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Viral carrier transport efficiency of gene delivery is high, depending on the
type of vector. However, viral delivery poses significant safety concerns such as
inefficient/unpredictable reprogramming outcomes, genomic integration, as well as
unwarranted immune responses and toxicity. Thus, non-viral gene delivery methods
are more feasible for translation as these allow safer delivery of genes and can
modulate gene expression transiently both in vivo, ex vivo, and in vitro. Based on
current studies, the efficiency of these technologies appears to be more limited, but
they are appealing for clinical translation. This review presents a summary of recent
advancements in orthopedics, where primarily bone and joints from the musculoskeletal
apparatus were targeted. In connective tissues, which are known to have a poor
healing capacity, and have a relatively low cell-density, i.e., articular cartilage, bone,
and the intervertebral disk (IVD) several approaches have recently been undertaken. We
provide a brief overview of the existing technologies, using nano-spheres/engineered
vesicles, lipofection, and in vivo electroporation. Here, delivery for microRNA (miRNA),
and silencing RNA (siRNA) and DNA plasmids will be discussed. Recent studies will
be summarized that aimed to improve regeneration of these tissues, involving the
delivery of bone morphogenic proteins (BMPs), such as BMP2 for improvement of bone
healing. For articular cartilage/osteochondral junction, non-viral methods concentrate on
targeted delivery to chondrocytes or MSCs for tissue engineering-based approaches.
For the IVD, growth factors such as GDF5 or GDF6 or developmental transcription
factors such as Brachyury or FOXF1 seem to be of high clinical interest. However, the
most efficient method of gene transfer is still elusive, as several preclinical studies have
reported many different non-viral methods and clinical translation of these techniques
still needs to be validated. Here we discuss the non-viral methods applied for bone and
joint and propose methods that can be promising in clinical use.
Keywords: non-viral gene delivery, bone, tendon, cartilage, intervertebral disk, GDF5, FOXF1, BMP2
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INTRODUCTION
Non-viral gene therapy holds great premises as it is assumed
to be less toxic for the host and much safer in terms of
gene delivery compared to viral vectors (NIH Report, 2002;
Kaiser, 2007).
Generally, gene transfer approaches in clinical trials are
much less common than clinical trials in general that may
involve drug testing (Figure 1). In the clinical trial register
(clinicaltrials.gov accessed on 9-October-2020) there were 5,013
(60%) studies reported on “general bone diseases,” 1,034
(11%) on the “hip”-joint, 600 (7%) studies on “rotator cuff,”
1,002 (12%) studies on “tendon” repair, 337 (5%) studies
on “intervertebral disk degeneration” (IVD), and 379 (5%)
studies on cartilage repair (“cartilage”) (Figure 1). However,
with the additional mesh-terms “gene delivery” OR “viral
gene therapy” combined with the afore-mentioned orthopedic
“specialties” 289 studies were identified for “bone,” only two
for the “tendon” and five were found for “IVD” and none for
“cartilage” (inlet, Figure 1). Finally, “non-viral” AND “gene
delivery” resulted in “zero” studies in all fields of orthopedics.
This fact reflects the current situation of non-viral gene
delivery trials in this field. One reason might be that the
search for new gene therapies, which target certain tissues
and cells, has become more cumbersome due to increased
levels of regulation (Boissier and Bessis, 1997; Evans et al.,
2006, 2012). Many of the recently developed products have
not been translated into the clinics, for which many reasons
have been identified. One important aspect is safety. The risks
and the acceptance of viral gene transfer methods experienced
have been affected by sudden patient deaths, such as the
examples of Jesse Gelsinger and Joli Mohr (Wilson, 2009;
Yarborough and Sharp, 2009). Thus, non-viral gene therapy
seems an attractive alternative to viral gene delivery and is
an new and emerging field being applied to regenerative
medicine. It offers a safer approach to viral vectors with lack
of immunogenicity and host genome integration. However, pre-
clinical application of such technologies to the musculoskeletal
field is still limited.
Many of the alternate approaches are less efficient than viral
delivery systems (NIH Report, 2002; Pranatharthiharan et al.,
2013; O’Reilly et al., 2015) and due to necessary optimization
Abbreviations: AAV, adenoviral vector; ADAMTS5, A Disintegrin and
Metalloproteinase with Thrombospondin motifs 5; ASCs, adipo-tissue-
derived mesenchymal stromal cells; BMPs, bone morphogenic proteins;
CAP, chondrocyte-affinity peptide; CGMS, composites of cationized gelatin
microspheres; GAG, glycosaminoglycans; GMP, good manufacturing practice;
GDS, gene delivery systems; HA, hyaluronic acid; hBMSCs, human bone-
marrow-derived mesenchymal stromal cells; hTERT, human telomerase
reverse transcriptase; EP, electroporation; ECM, extracellular matrix; EVs,
extracellular vesicles; FITC, fluorescein isothiocyanate; IVD, intervertebral
disk; IVDD, intervertebral disk degeneration disease; LNPs, lipid nucleic acid
nanoparticles; LTI, lysine-tri-isocyanate; MiRNA, micro-RNA; MMP, matrix
metalloproteinase; MSC, mesenchymal stromal cell; MPMs, mixed polyplex
micelles; MVs, matrix vesicles; N.D., non-determined; NVGD, non-viral gene
delivery; OA, osteoarthritis; PAMAM, polyamidoamine dendrimers; pBMP-
2, plasmid containing BMP-2; PDGF, platelet-derived growth factor; pDNA,
plasmid DNA; PEI, poly-ethylene-imine; PLGA, Poly(D,L-lactide-coglycolide)
lactide:glycolide acid; PTH, parathyroid hormone; siRNA, silencing RNA; VEGF,
vascular endothelial growth factor.
that is required increases developmental costs exponentially as
the product approaches market release (Epstein, 1991; Evans
et al., 2012). Another current challenge lies in the experimental
designs of clinical trials, which, if not properly planned or
randomized, produce doubtful conclusions. As for clinical trials,
it needs to be mentioned and clarified if appropriate placebo
controls were considered in the original experimental set-up
(NIH Report, 2002; Wilson, 2009). In the absence of properly
designed controls, it may be impossible to determine whether
observed toxicity is due to an underlying disease or the use of
a specific vector.
In orthopedic research there are a number of significant
health burdens that urgently warrant better therapeutic
solutions. In addition to bone metabolic diseases, this also
includes problematic musculoskeletal degenerative pathologies
of cartilage, tendons, and ligaments, as well as the intervertebral
disks (IVDs) of the spine. It has been identified that osteoarthritis
(OA) (Wittenauer et al., 2013) and low back pain (LBP)
caused by degenerative changes in the IVD are two of the
significant global clinical problems to be tackled in the future
(GBD 2017 Disease and Injury Incidence and Prevalence
Collaborators, 2018). With an increasing elderly population, the
demand for joint-replacement surgeries has risen exponentially.
For many of the degenerated joints, whether due to aging,
genetic predisposition, or trauma, pure mechanical implant
solutions exist until now. These do not necessarily take into
account the natural tissue properties. Here, in particular
in the field of early prevention, non-viral gene therapy
could become highly relevant in the near future and is the
focus of this review. Here we evaluate promising in vitro
and in vivo non-viral methods being utilized and more
specifically in cartilage, the intervertebral disk and bone and
gaps/areas that need to be addressed to move these non-viral
strategies forward.
OVERVIEW OF NON-VIRAL VEHICLE
METHODS
Gene delivery in general may involve the packaging of DNA
or RNA in so-called “vectors” but can also be delivered
naked (Patil et al., 2019). Generally, one can classify
methods according to the approach to overcome the cell’s
phosphobilayer membrane: There are “carrier-free” methods
that use physical penetration (e.g., electroporation, gene
gun, laser, microinjection) or there are methods that use
so-called “carriers,” in which DNA or RNA is packed into
lipo-philic particles, so-called liposomes, or similar (Figure 2).
A distinction can also be made between methods that use
fluorescence to monitor the success of the gene transfer
or methods that lack this practical feature to monitor the
efficiency (Patil et al., 2019). There are several commercial
suppliers offering kits that pack DNA or RNA into liposomes
and then transfect cells in vitro (Figure 2). However, the
success of these transfections and duration of the changes
may be extremely dependent on the cell-type and the vectors.
In some cases, a short over-expression of particular genes
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FIGURE 1 | Number and percentages of clinical trials accessed on the 9-October-2020 at ClinicalTrials.gov for different fields in orthopedics, and for inlet limiting the
search for the search terms “gene delivery” OR “viral gene therapy” AND the respective area in orthopedics, i.e., “general bone diseases,” “hip,” “tendon,” “cartilage,”
and “intervertebral disk degeneration.”
is even a warranted side-effect. The advantages of non-viral
gene therapy are the fact that the effects are not long-
lived. In the following sections, we will briefly introduce
the different methods.
Lipofection/Lipid-Based Vectors
Lipofection via liposomes or lipoplexes has been widely
utilized to deliver genetic cargo to cells in vitro. This
method involves encapsulating pDNA, siRNA, or MicroRNA in
spheroids with hydrophilic polar head groups and hydrophobic
tails, similar to the structure of the cell membrane (Felgner
et al., 1987; Torchilin, 2005). One of the earliest and
popular lipofection systems involved cationic lipid, N-[1-
(2,3-dioleyloxy)propyl]-N,N, N-trimethylammonium chloride
(DOTMA). However, due to initial limitations associated with
non-specific protein binding (Lv et al., 2006), more recent
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FIGURE 2 | Overview of non-viral approaches for gene delivery to cells in orthopedics. One may generally categorize the methods into (A) physical penetration
methods (in blue panel) versus (B) chemical carriers, i.e., methods involving carriers such as lipofection, micro vesicles, and EVs and, the usage of nanoparticles.
iterations have included modifications such as neutral helper
lipids to reduce cytotoxicity and to improve the efficiency of the
transfection (Gao and Hui, 2001; Dabkowska et al., 2012). These
improvements led to the development of lipid nanoparticles,
which are formed from cationic lipids with both neutral helper
lipids and ionizable cationic amino head groups (Wheeler et al.,
1999). These systems can readily form complexes with large
nucleic acid constructs and have many advantages such as
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efficient in vitro delivery, biodegradability and the option to tune
as well as to functionalize them as described in Table 1. Yet the
efficiency of in vivo transfection is more limited with these lipid-
based methods, as is the optimization of formulations for mass
manufacturing. In orthopedics, lipid-based vectors for non-viral
gene delivery have been widely utilized (Table 1) such as for
treatments for osteoporosis, arthritis, and the IVD.
Electroporation
Electroporation (electro-permeabilization) is a physical method
based on the application of high voltage pulses for a short
duration to facilitate cellular uptake of nucleic acids or drugs.
The concept of electroporation was pioneered by Neumann
et al. (1982), and since then it has become a standard method
of in vitro transfection due to its low cost and safety (Wong
and Neumann, 1982). Optimized electric pulses increase the
permeability of the cell membrane through which nucleic acid
or drug can enter the cell, once the pulses are terminated the
cell membrane rapidly recovers and closes (Gowrishankar et al.,
1999; Somiari et al., 2000; Gehl, 2003; Glover et al., 2005; Mehier-
Humbert and Guy, 2005; Liu et al., 2006; Al-Dosari and Gao,
2009; Boukany et al., 2011; Guo and Huang, 2012; Mellott et al.,
2013; Wang et al., 2013; Song et al., 2015; Tschon et al., 2016;
Tsuchiya et al., 2017; Vroomen et al., 2017; Kawai et al., 2018;
Melancon et al., 2018; Shapiro et al., 2018; Shi J. et al., 2018;
Tang W. et al., 2019; Bono et al., 2020) (Table 1). Over the years,
electroporation has also been applied for in vivo application, with
most applications for preclinical models in skin (Jafari et al.,
2018; Pasquet et al., 2018), lung (Gazdhar et al., 2006; Gazdhar
et al., 2007) heart (Ayuni et al., 2010; Hargrave et al., 2014;
Sugrue et al., 2020) diaphragm (Beshay et al., 2009), liver (Heller
et al., 1996; Kobayashi et al., 2003), tumor (Goepfert et al., 2011),
cornea (Zhou and Dean, 2007), retina (Matsuda and Cepko,
2004; Lirong et al., 2014), brain (Inoue and Krumlauf, 2001;
De Fry et al., 2010; Nomura et al., 2016), artery and muscle
(Zhang et al., 2001; Molnar et al., 2004; Tavakoli et al., 2006;
Sokołowska and Błachnio-Zabielska, 2019).
In vivo electroporation is dependent on various parameters.
Therefore, studies have been conducted over to optimize the
electrical impulse protocol (voltage, number, and type of pulses),
estimation of the interval between the injection of therapeutics
and the delivery of electrical pulses, electrode geometry and
tissue properties to increase the efficiency of electroporation
(Satkauskas et al., 2012; Haberl et al., 2013; Shi B. et al., 2018;
Hyder et al., 2020). The mechanism of electroporation mediated
nucleic acid and drug delivery is still under investigation.
However, detailed research shows that it is a multistep process
and involves (i) permeabilization of the plasma membrane
under the influence of an electric field, (ii) migration of the
DNA/drug toward membrane by electrophoretic forces (iii) and
translocation across the membrane. Importantly the mechanisms
studied in vitro cannot be exactly transferred for in vivo
electroporation. However, it is agreed that under the influence of
an electric filed the cell membrane is being electropermeabilized,
which leads to electrophoretically driven migration of nucleic
acids and drugs through the target tissue. Therefore, high voltage
(HV) and low voltage (LV) pulses have been studied, and their
effects have been tested for electropermeabilization.
Various electrodes are used depending on the target site and
are of different size shapes and made of different materials. Most
commonly, the electrodes are made of stainless steel, copper,
titanium, and they differ in their electrical conductivity, price,
and corrosion (Rebersek et al., 2014). For the clinical purpose,
electrodes made of stainless steel and titanium are used. Recent
recommendations suggest using electrodes with a gallium core so
that they can absorb the heat generated and thus protect the tissue
(Kotnik et al., 2001; Arena et al., 2013). The most commonly
used electrodes are either plate electrodes or needle array
electrodes. Furthermore, nanochannel-based electroporation has
been reported for various applications in Orthopedic research
(Boukany et al., 2011; Geng and Lu, 2013; Wang and Lee, 2013;
Xie et al., 2013; Gao et al., 2014; Chang et al., 2016; Gallego-Perez
et al., 2016, 2017; Shi J. et al., 2018) (Table 1).
Engineered Vesicles/Exosomes
Extracellular Vesicles (EVs) are cell-derived, lipid membrane
enclosed nanoscale particles capable of packaging proteins, lipids,
and genetic cargo such as DNA and various RNAs as summarized
by O’Brien et al. (2020). They are used for intercellular
communication and are excreted by nearly all cells in the body
leading to their isolation from most bodily fluids including blood,
urine, saliva, amniotic and synovial fluids via ultracentrifugation
(Simpson et al., 2008; Andaloussi et al., 2013; Properzi et al., 2013;
De Jong et al., 2014; Mulcahy et al., 2014; Lamichhane et al., 2015;
Yáñez-Mó et al., 2015; Tkach and Théry, 2016; Maas et al., 2017;
Xie et al., 2017; Diomede et al., 2018; Li et al., 2018; van Niel
et al., 2018; Marolt Presen et al., 2019; Pizzicannella et al., 2019;
Trubiani et al., 2019). Historically, they have been categorized
into three main classes mainly based on particle size and
biogenesis: Exosomes (40–120 nm) via endolysosomal pathway,
Microvesicles/Microparticles (50–1,000 nm) via budding from
plasma membrane, and Apoptotic bodies (1–5,000 nm) via
blebbing from plasma membrane (Andaloussi et al., 2013; Rilla
et al., 2019). However, overlap in the size of these vesicular
bodies along with their heterogeneous population, has resulted in
interchangeability between the nomenclature (Kowal et al., 2016;
Tkach et al., 2017). Thus, micro-vesicles and exosomes will be
referred to as EVs in this review.
In general, EVs consist of a lipid bilayer membrane composed
of tetraspanins (CD9, CD63, CD81, CD82), integrins, and cell-
specific receptors for cell-to-cell communication and internal
cargo as described in Wu et al. (2019). Their composition
allows for the transmission of proteins, bioactive lipids, and
genes, which can alter the function and phenotype of target cells
(Andaloussi et al., 2013). Besides, different surface molecules
can facilitate ligand-receptor signaling for targeting, adhesion,
and fusion to the recipient cell (Boere et al., 2018). Cell-
derived EVs can be engineered to carry exogenous genes
as a non-viral delivery system as described by Gallego-
Perez et al. (2017) via generating EVs from autologous mice
fibroblasts and reprogramming them with a cocktail of exogenous
of transcription factors into neuronal and endothelial cells.
Furthermore, MSC-derived EVs have received growing interest
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TABLE 1 | Advantages and limitations of non-viral gene delivery methods.
Method Advantages Limitations Applications
Electroporation
(Gehl, 2003; Wells, 2004; Glover et al.,
2005; Mehier-Humbert and Guy, 2005;
Liu et al., 2006; Al-Dosari and Gao,
2009; Boukany et al., 2011; Guo and
Huang, 2012; Mellott et al., 2013;
Wang et al., 2013; Song et al., 2015;
Tschon et al., 2016; Tsuchiya et al.,
2017; Vroomen et al., 2017; Kawai
et al., 2018; Melancon et al., 2018;
Shapiro et al., 2018; Shi B. et al., 2018;
Tang S. et al., 2019; Bono et al., 2020)
Rapid and straightforward transfection method.
Well established protocols for a wide variety of cell lines.
High throughput, with the possibility to handle millions of cells
per transfection.
It can potentially be applied to transfect both dividing and
non-dividing cells.
Previous studies have reported 100- to 1000-fold increase in
gene expression compared to direct injection of naked DNA for
transfected tissues (e.g., spinal cord, and cardiac and skeletal
muscle).
Transfection efficiency varies significantly
depending on the cell line or tissue of origin
Limited cell viability due to the high magnitude
and non-uniform voltage used (in this method
the entire cell surface is exposed to a high
intensity electric field), pH changes, and joule
heating.
High-intensity electric field can lead to DNA
instability.
Requires direct access/contact with the target
tissue, and a large area of tissue for effective
transfection.
Transfection efficiency can be limited by cargo
size.
Stochastic transfection profile, where the
transgene expression is not homogeneously
distributed in the cells/tissue
Cargo delivery mechanisms driven in part by
endocytosis and endosomal escape, and
mediated by binding of the molecular cargo to
the cell surface, which may limit transfection
efficiency.
Spinal cord and spinal nerves (Tschon et al., 2016)
Periodontal tissue (Kawai et al., 2018)
Tibial tumor (Melancon et al., 2018)
Tumors in liver, lung, and kidney (Vroomen et al.,
2017)
Bone – Femur (Song et al., 2015)
Periodontal ligament (Tsuchiya et al., 2017)
IVD (Bucher et al., 2013; May et al., 2017; Tang S.
et al., 2019)
Skin (Jafari et al., 2018; Pasquet et al., 2018)
Lung (Gazdhar et al., 2006; Gazdhar et al., 2007)
Heart (Ayuni et al., 2010; Hargrave et al., 2014;
Sugrue et al., 2020)
Diaphragm (Beshay et al., 2009)
Liver (Heller et al., 1996; Kobayashi et al., 2003)
Tumor (Goepfert et al., 2011)
Cornea (Zhou and Dean, 2007)
Retina (Matsuda and Cepko, 2004; Lirong et al.,
2014)
Brain (Inoue and Krumlauf, 2001; De Fry et al.,
2010; Nomura et al., 2016)
Artery and muscle (Matsumoto et al., 2001; Zhang
et al., 2001; Molnar et al., 2004; Tavakoli et al.,
2006; Sokołowska and Błachnio-Zabielska, 2019)
Nanochannel-based
electroporation
(Boukany et al., 2011; Geng and Lu,
2013; Wang and Lee, 2013; Xie et al.,
2013; Gao et al., 2014; Chang et al.,
2016; Gallego-Perez et al., 2016;
Gallego-Perez et al., 2017;
Shi B. et al., 2018)
Higher cell viability (approx. 100%), due to selectivity of the cell
membrane depending on the size and location of the
nanochannels, with <1% of the cell membrane being exposed
to the high electric field.
High transfection efficiency (81–>95% depending on
nano-channel configuration and molecular cargo).
Deterministic transfection profile, which leads to high
reproducibility.
Cargo delivery is solely regulated by electrophoresis forces,
which significantly increases the speed of transfection
(approximately 3000 times faster compared to bulk
electroporation), circumventing endocytosis and endosomal
escape.
Requires direct contact with the cell/tissue.
Direct delivery is restricted to the outer most
cell layer of the tissue.
Induction of pluripotent stem cells (iPSC) (Wang
and Lee, 2013; Gao et al., 2014)
In vivo reprogramming of skin cells into functional
induced-neurons and -endothelial cells
(Gallego-Perez et al., 2017)
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TABLE 1 | Continued
Method Advantages Limitations Applications
Dosage control capabilities by adjusting transfection
parameters (i.e., voltage, duration, number of pulses).
Tissue-nano transfection enables transfection of large sections
of tissues in vivo. For this method transfection efficacy has been
reported to be around 50–250-fold higher compared to
standard bulk electroporation (Gallego-Perez et al., 2017).
Sonoporation
(Mehier-Humbert and Guy, 2005;
Sheyn et al., 2008a; Al-Dosari and Gao,
2009; Wang et al., 2013; Kawai et al.,
2018; Bono et al., 2020)
Method that can transfer therapeutic agents into the target cells
without surgical intervention (i.e., non-invasive).
Enables localized treatment.
This method is coupled with real time imaging during the
procedure, which allows for closer control of molecular cargo
delivery at specific tissue locations.
Low transfection efficiency in vitro
(approximately 30%).
Low reproducibility as its transfection profile is
highly stochastic.
May cause tissue damage due to overheating
conditions.
Limited control of energy localization.
Bone engineering (Sheyn et al., 2008a; Feichtinger
et al., 2014; Kawai et al., 2018)
Tissue regeneration (Nomikou et al., 2016)
IVD (Nishida et al., 2006)
Biolistic gene delivery (Gene gun)
(Kitagawa et al., 2003; Zhu et al., 2004;
O’Brien and Lummis, 2006; Al-Dosari
and Gao, 2009; Su et al., 2012; Wang
et al., 2013; Bono et al., 2020)
Can be applied to a wide variety of cells/tissues
Moderate transfection efficiency (around 30–40% in vitro)
especially for DNA vaccination due to its ability to induce a
higher immune response using a lower DNA dose (with up to
100- to 1000-fold increase in antibody production).
Ability to transfect non-dividing cells.
Expensive device, reagents, and supplies are
required.
Can cause significant cell damage due to
extensive cell membrane damage.
Accumulation of carriers (e.g., gold/tungsten)
inside the cells may have a negative impact on
cell function.
Low reproducibility as its transfection profile is
highly stochastic.
Transfection efficiency and consistency depend
on effective and consistent coating of carriers
with the molecular material.
Transient transgene expression due to random
delivery.
Limited tissue depth penetration (less than
1 mm into the skin).
Lacks cell specificity.
Immunization (Nomikou et al., 2016)
Cancer gene therapy (Kitagawa et al., 2003)
Engineered extracellular vesicles
(microvesicles and exosomes)
(Andaloussi et al., 2013; De Jong et al.,
2014; Mulcahy et al., 2014;
Lamichhane et al., 2015; Yáñez-Mó
et al., 2015; Tkach and Théry, 2016;
Maas et al., 2017; Xie et al., 2017;
Diomede et al., 2018; Li et al., 2018;
van Niel et al., 2018; Marolt Presen
et al., 2019; Pizzicannella et al., 2019;
Naturally derived nanocarriers with low immunogenicity.
Transfection efficiencies have been reported to vary depending
on multiple factors, including size of molecular cargo,
extracellular vesicle size and aggregation, and type/origin of
recipient cell/tissue.
High cargo delivery efficiency.
Low cytotoxicity.
Can be functionalized for targeted delivery.
Innate ability to permeate biological barriers and deliver cargo
to target cells.
When directly isolated from non-engineered
donor cells may present low reproducibility due
to its cargo heterogeneity (influenced by cell
type or tissue of origin and isolation methods).
Methods to engineer EVs/exosomes
post-isolation can be cumbersome and
labor-intensive.
Regenerative medicine (Lamichhane et al., 2015)
Periodontal ligament (Pizzicannella et al., 2019)
Bone tissue repair (Diomede et al., 2018; Li et al.,
2018; Chen et al., 2019; Marolt Presen et al., 2019;
Trubiani et al., 2019)
Joint diseases (OA and periprosthetic infections)
(Wu et al., 2019; Rüwald et al., 2020)
Soft tissue repair (Mendt et al., 2019)
Cartilage regeneration using MSCs (To et al., 2020)
Orthopedic tissues (Cappariello et al., 2018)
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Frontiers
in
B
ioengineering
and
B
iotechnology
|w
w
w
.frontiersin.org
7
N
ovem
ber
2020
|Volum
e
8
|A
rticle
598466
fbioe-08-598466
N
ovem
ber17,2020
Tim
e:12:17
#
8
G
antenbein
etal.
N
on-viralG
ene
Therapy
for
B
one
and
Joints
TABLE 1 | Continued
Method Advantages Limitations Applications
Pomatto et al., 2019; Trubiani et al.,
2019)
High stability in biological fluids and circulation.
Size of molecular cargo is not limited by capsid size restrictions.
Ability to pack diverse molecular cargo and therapeutic agents.
Lipo/polyplex-based carriers
(De Laporte et al., 2006; Basarkar and
Singh, 2007; Ditto et al., 2009; Guo
and Huang, 2012; Su et al., 2012;
Jones et al., 2013; Foldvari et al., 2016;
Patil et al., 2019)
Cationic lipoplexes have facilitated cellular uptake due to their
positive charge.
Can be functionalized with specific ligands to achieve targeted
delivery.
Moderate transfection efficiency in vitro (40–50%).
Tunable features (e.g., size, surface properties, molecular cargo)
Ability to deliver large DNA constructs.
Cargo delivery relies heavily on endocytosis and
endosomal escape.
High cytoxicity at higher concentrations (>3:1
lipid: DNA ratio)
Low transfection efficiency in vivo due to its
limited circulation half-life in blood.
Non-biodegradable polyplex carriers may
accumulate in tissues over time.
Cumbersome and labor-intensive production
protocols, which limit scalability and
reproducibility.
IVD (Kakutani et al., 2006; Chung et al., 2007;
Morrey et al., 2008; Sudo and Minami, 2011;
Banala et al., 2019)
Bone (Winn et al., 2005; Macdonald et al., 2007;
Oliveira et al., 2009; Guo-ping et al., 2010; Yan
et al., 2014; Monteiro et al., 2014)
Synthetic polymer-based carriers
(Anderson and Shive, 1997; Prokop
et al., 2002; Eliyahu et al., 2005; Pack
et al., 2005; De Laporte et al., 2006;
Basarkar and Singh, 2007; Ditto et al.,
2009; Tzeng et al., 2011; Guo and
Huang, 2012; Su et al., 2012; Jones
et al., 2013; Foldvari et al., 2016; Patil
et al., 2019)
High biocompatibility.
Highly effective to prevent molecular cargo degradation and
increase stability (e.g., for DNA)
Tunable features (e.g., size, surface properties, molecular
cargo).
Possibility to modulate release rate over time.
Ability to be synthesized on a large scale.
Transfection efficiencies in the range of 50–75%.
Dendrimer configuration enhances gene expression up to
50-fold compared to the bulk polymer.
High cytoxicity at higher concentrations (> 25
kDa)
Low transfection efficiency in vivo due to its
limited circulation half-life in blood (in the range
of minutes for some preparations).
Small non-degradable polymer carriers may
accumulate in tissues over time (e.g., lung and
liver).
Significant batch to batch variability (e.g., large
size distribution, and non-homogenous packing
of molecular cargo) depending on fabrication
method.
IVD (Feng et al., 2015; Feng et al., 2017)
Bone tissue engineering (Dimitriou et al., 2011;
Pereira et al., 2020)
Bone (Tierney et al., 2012) ch (Itaka et al., 2007;
Reckhenrich et al., 2012; Nguyen et al., 2014)
Natural polymer-based carriers
(Katas and Alpar, 2006; Ji et al., 2009;
Yuan et al., 2010; Garcia-Fuentes and
Alonso, 2012)
High biocompatibility.
Lower cytotoxicity compared to synthetic polymer- and
lipid-based carriers.
Natural polymers promote more efficient uptake due in part to
their ability to cross biological membranes.
Transfection efficiency in vitro in the range of 30–50% and
50–70% for upregulating or downregulating gene expression,
respectively.
Ability to be bacteriostatic and anti-inflammatory.
Can be used to for applications requiring redosing, as the
carrier material will normally degrade in the body.
Ability to enhance tumor accumulation
compared to naked siRNA.
Low transfection efficiency in vivo.
Cancer treatment using chitosan vectors packed
with siRNA (Katas and Alpar, 2006)
Bone tissue engineering (Bourgeat-Lami, 2002;
Kasper et al., 2005, 2006; Stevens et al., 2005;
Park et al., 2007; Chew et al., 2011; Wegman
et al., 2011, 2014)
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Inorganic-gold nanoparticles
(Olton et al., 2007; Arvizo et al., 2010;
Ding et al., 2014; Wegman et al., 2014;
Das et al., 2016; Yang et al., 2018)
High biocompatibility.
Tunable features (e.g., size and surface coatings).
Can be easily functionalized with specific ligands to achieve
targeted delivery.
Relatively low immunogenicity and cytotoxicity in vitro.
Transfection efficiency comparable to lipoplexe-based carriers
(in the range of 40–55%).
Photothermal and other physical properties enable potential
implementation in thermal ablation, as contrast agents, or to
guide them towards specific tissue niches in the body.
Significant batch to batch variability depending
on synthesis technique.
Since these carriers present high chemical
stability in biological fluids, accumulation inside
the cells may have a negative impact on cell
function (e.g., cell growth, and tissue viability).
Bone tissue engineering (Olton et al., 2007;
Wegman et al., 2014)
Carbo Nanotubes
(Cai et al., 2005; Liu et al., 2005; Tian
et al., 2006; Harrison and Atala, 2007;
Moradian et al., 2014; Karimi et al.,
2015)
Thermal conductivity.
Electrical and mechanical properties.
Strength and flexibility.
Stability under biological fluids.
Ability to sustain release and promote selectivity
Can be functionalized to enhance transfection efficiency and
targeted delivery.
Ability to escape lysosomal pathway.
High surface area (∼1300 m2/g for closed, single-walled
carbon nanotube).
Transfection efficiency approximately 4 orders of magnitude
higher than for naked DNA.
High fabrication cost.
Non-biodegradable.
Limited solubility.
Low stability under biological fluids, due to
possible aggregation.
Cytotoxicity and transportation efficiency
dependent on their surface functionalization,
physical properties, and/or synthesis method.
Tissue engineering
(Harrison and Atala, 2007)
Drug and gene delivery (Cai et al., 2005; Tian et al.,
2006; Moradian et al., 2014; Karimi et al., 2015)
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due to their therapeutic potential for joint diseases such as
OA and periprosthetic infections, and further characterization
of specific therapeutic genetic factors will produce EVs with
enhanced regenerative potential (Wu et al., 2019; Rüwald
et al., 2020). Thus, these EVs can be engineered both via
modification of genetic cargo (electroporation, lipofectamine,
siRNA, etc.) or alteration of the EV surface proteins for desired
targeting and gene delivery, as summarized in two recent
reviews (Sutaria et al., 2017; Mentkowski et al., 2018). EVs offer
benefits over conventional delivery systems such as polymers
and liposomal systems in terms of stability, immunogenicity,
and biocompatibility. Since EVs are generated from innate cells
of the body, their size and membrane composition allow for
avoidance of degradation in vivo through pathways such as
lysosomal degradation, endosomal pathway, phagocytosis, or
degradation by macrophages as reviewed in Ha et al. (2016).
Their small size allows for long term systemic delivery along
with the ability to cross the blood-brain barrier and deliver
genetic cargo directly into target cell cytosol with high efficiency
(Kooijmans et al., 2012; Tran et al., 2015). As EVs are generated
from almost all cell types, they are abundant in quantity and
can be derived from desired cell types to contain surface
markers for cell-specific targeting. They also have advantages
over cell therapy due to decreased immunogenicity compared
to parent cells because of lower trans-membrane MHC proteins
and longer shelf life (Ong and Wu, 2015). Despite these
advantages, there are some technical and biological challenges
still associated with EVs.
Firstly, there are many underexplored areas in EV research,
such as their population heterogeneity, differences in isolation
methods, and reproducibility, as described in O’Brien et al.
(2020). Heterogeneity in EVs can differ between sample to sample
as well as within batches due to differences between cell types,
culture conditions, and lack of determining specific biomarkers
(Nolte-’t Hoen and Wauben, 2012). Isolation methods also vary
amongst the field, resulting in heterogeneously isolated EVs
with inconsistent naming conventions and make reproducibility
difficult (Malda et al., 2016). Besides, their small size also poses
disadvantages, as there may be undesired systemic circulation of
the generated EV throughout the body. Contradictory findings
have also been observed demonstrating the complex nature of
EVs such as MSC-derived EVs that both inhibit and promote
tumor growth, although EVs themselves do not exhibit the ability
to form tumors (Zhu et al., 2012; Bruno et al., 2013).
Current EV related research has primarily focused on MSC
derived exosomes, and many are in clinical trials for the treatment
and repair of soft tissues (Mendt et al., 2019). Very recently, a
systematic review has been conducted on the application of EV to
regenerate cartilage using MSCs (To et al., 2020). In these models,
all studies that involved MSC-EVs reported less loss of cartilage
with the implementation of EVs compared to placebo (To et al.,
2020). MicroRNA delivery using EVs has also been a large area
of interest. It has shown effects on cell migration, angiogenesis,
cell proliferation, and osteogenic differentiation of target cells
as summarized in O’Brien et al. (2020). Current research on
exosomes/EVs is focused on innate EVs without engineering and
their treatment of target cells/tissue. In terms of gene delivery
using EVs for orthopedic tissues, this is an unexplored area of
research. Thus, EVs demonstrate significant therapeutic potential
for non-viral gene delivery due to their intrinsic biocompatibility,
low immunogenicity/cytotoxicity, stability, diverse cargo, and
engineering capacity. However, there is more elucidation desired
before EVs can be used as a gene delivery vehicle in the
clinical setting.
Synthetic Polymer-Based Gene Vectors
Synthetic polymers, both degradable and non-degradable, have
several characteristics that make them suitable for gene vector
delivery, including biocompatibility, low immunogenicity,
high affinity for nucleic acids, improved stability in biological
fluids, and the ability to be engineered to mediate cellular entry
and endosomal escape (e.g., via hydrophobic modifications)
(Anderson and Shive, 1997; Prokop et al., 2002; Pack et al.,
2005; Patil et al., 2019). Moreover, their tunable properties
and molecular flexibility enable functionalization with specific
targeting moieties to favor cell-specific uptake, or conjugation
with fusion tags to confirm successful gene delivery (Eliyahu
et al., 2005; Guo and Huang, 2012; Foldvari et al., 2016; Patil et al.,
2019). Cationic synthetic polymers such as polyamidoamine
(PAMAM) dendrimers, polyethyleneimine (PEI), poly[2-
(dimethylamino)ethyl methacrylate] (PDMAEMA), poly-Lysine,
and polyamidoamine-epichlorohydrin (PAAE), have been
widely used for gene delivery applications due to their positive
charge, which facilitates genetic cargo loading mediated by their
electrostatic interaction with the negatively charged nucleic
acids, as well as cellular uptake (De Laporte et al., 2006; Basarkar
and Singh, 2007; Patil et al., 2019). Although polycationic-based
vectors, such as PEI and PAMAM dendrimers have shown to be
effective vehicles for siRNA and miRNA delivery, their highly
positive charge may lead to non-specific interactions with the
negatively charged phospholipid membrane of circulating cells
after systemic delivery (Guo and Huang, 2012; Patil et al., 2019).
Cationic polymers can also be modified to modulate their binding
strength to the genetic material to achieve successful nucleic acid
transfer while still providing viable protection from enzymatic
degradation (Jones et al., 2013). The stability of these synthetic
polymers can be significantly influenced by their molecular
weight, where small complexes with lower molecular weight can
be more unstable under physiological conditions, resulting in
molecular cargo unpacking, degradation, and clearance (Su et al.,
2012). As these small complexes require higher concentrations to
achieve adequate gene regulation, if not correctly stabilized, they
can aggregate and form larger complexes that can accumulate
overtime in organs such as the lung and liver, which significantly
impacts cell/tissue function and leads to higher toxicity (Su et al.,
2012). A similar phenomenon can be observed for synthetic
polymers with higher molecular weight (>25 KDa) (Su et al.,
2012). This issue can be addressed by introducing specific surface
modifications, such as a PEG-conjugation, to improve steric
stabilization and reduce unwanted interactions with salts and
other charged or neutral particles present in the circulation (Pack
et al., 2005; Su et al., 2012; Jones et al., 2013). Polymers, on the
other hand, can help to overcome these limitations by preventing
accumulation of the carrier as the genetic material is delivered.
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For this type of polymer, size and degradation rate can be
optimized to favor rapid intracellular delivery (Ditto et al., 2009).
Advantages and Disadvantages of
Current Non-viral Gene Delivery Methods
Viral vectors have developed into the gold standard for
modulating gene expression in vivo thanks to their high
transfection efficiency and ability to bypass endocytosis to enter
the cytosol, especially when compared to synthetic transfection
methods such as lipo/polyplex-based carriers (Ziello et al., 2010).
However, although promising to obtained stable (when using
adeno-associated viruses) or transient (when using adenoviruses)
transfection of cells, viral vectors present significant limitations
due to the persistent risk of triggering immune reactions
which hinders the ability for redosing, limited size of the
molecular cargo due to capsid size restrictions, and potential
biosafety concerns for clinical applications (Daya and Berns,
2008; Joshi et al., 2017). To overcome these limitations
many non-viral physical and chemical/biological transfection
methods have been developed (e.g., electroporation-based
approaches, synthetic nanocarriers, and electro exosomes/EVs)
(Wu et al., 2013). However, some of these methods are still
limited for example by low stability in biological fluids for
synthetic nanocarriers, low transfection efficiency and electro-
toxicity for some electroporation-based methods such as bulk
electroporation since the entire cell surface is exposed to a
high-intensity electric field, and nanocarrier (i.e., gold/tungsten)
toxicity for biolistic transfection methods (Al-Dosari and Gao,
2009; Boukany et al., 2011; Wang and Lee, 2013). Nanochannel-
based electroporation approaches have emerged as a potent
tool to circumvent these limitations. In this type of technology,
nanochannel membranes are used to focus a high-intensity
electric field applied to the cell membrane, where only the cells
in contact with the nanochannels are porated, and the electric
field is only applied to a very small portion of the cell membrane
equivalent to the area of the nanochannel. This feature improves
cell viability and leads to a larger transmembrane potential
with enhanced transfection efficiencies and closer control over
molecular cargo transfer with a highly deterministic transfection
profile, compared to the stochastic profile observed when using
bulk electroporation (Boukany et al., 2011; Gallego-Perez et al.,
2016). More recently, Gallego-Perez et al. (2017) have used the
same governing physical principles to enable transfection of
tissues in vivo via Tissue Nano-Transfection to induce direct
cell reprogramming for regenerative applications (Gallego-Perez
et al., 2017). Table 1 provides an overview of advantages
and limitations for several widely used non-viral gene delivery
techniques, such as electroporation (Gehl, 2003; Wells, 2004;
Glover et al., 2005; Lin et al., 2005; Liu et al., 2005, 2006; Mehier-
Humbert and Guy, 2005; O’Brien and Lummis, 2006; Al-Dosari
and Gao, 2009; Boukany et al., 2011; Tzeng et al., 2011; Guo
and Huang, 2012; Mellott et al., 2013; Wang et al., 2013; Ding
et al., 2014; Song et al., 2015; Das et al., 2016; Tschon et al.,
2016; Tsuchiya et al., 2017; Vroomen et al., 2017; Kawai et al.,
2018; Melancon et al., 2018; Shapiro et al., 2018; Shi J. et al.,
2018; Pomatto et al., 2019; Tang S. et al., 2019; Bono et al., 2020),
Nanochannel-based electroporation (Boukany et al., 2011; Geng
and Lu, 2013; Wang and Lee, 2013; Xie et al., 2013; Gao et al.,
2014; Gallego-Perez et al., 2016; Chang et al., 2016; Gallego-Perez
et al., 2017; Shi J. et al., 2018), Sonoporation (Mehier-Humbert
and Guy, 2005; Sheyn et al., 2008a; Al-Dosari and Gao, 2009;
Wang et al., 2013; Balmayor and van Griensven, 2015; Kawai
et al., 2018; Bono et al., 2020), Biolistic gene delivery (Gene gun)
(Kitagawa et al., 2003; Zhu et al., 2004; Al-Dosari and Gao, 2009;
Su et al., 2012; Wang et al., 2013; Bono et al., 2020), engineered
EVs (microvesicles and exosomes) (Andaloussi et al., 2013; De
Jong et al., 2014; Mulcahy et al., 2014; Lamichhane et al., 2015;
Yáñez-Mó et al., 2015; Tkach and Théry, 2016; Maas et al., 2017;
Xie et al., 2017; Diomede et al., 2018; Li et al., 2018; van Niel
et al., 2018; Marolt Presen et al., 2019; Pizzicannella et al., 2019;
Trubiani et al., 2019).
NON-VIRAL GENE DELIVERY TO
ARTICULAR CARTILAGE
Articular cartilage degeneration is a severe pathology and affects
about three out of 10 people worldwide (Evans and Robbins,
1999; Wittenauer et al., 2013). There is an increase in interest
to deliver gene therapy to the cartilage to rescue or activate
remaining chondrocytes or to drive MSCs toward chondrocytes
(Evans and Robbins, 1999; Huizinga, 1999; Burstein, 2001; Im,
2016). The clinical problem is that hyaline cartilage cannot
be easily regrown ex vivo, although the chondrocytes can be
expanded after isolation. However, the quality of the matrix
that these cells produce differs from native tissue and with
inferior biomechanical properties (Gelse et al., 2003). Most
methods that have been proposed so far involve the removal
of chondrocytes and the ex vivo cell expansion, and then in a
second step, the cells will be treated with non-viral gene delivery
approaches, such as TGFβ, other Bone Morphogenic Proteins
(BMPs), or other anabolic genes such as insulin-like growth
factor-1 (IGF-1) (Saraf and Mikos, 2006). It has also been shown
that autologous chondrocytes seem challenging for successful
transfections and other cell sources as adipose or bone-marrow-
derived MSCs may be more promising (Heyde et al., 2007).
Addressing anti-inflammatory pathways by incorporation of IL-
10 or similar cytokines has been tested with promising results
(Khoury et al., 2006).
Lipid-Based Gene Vectors for Cartilage
Repair
Lipids were successfully used in a three-step method to achieve
high efficiency of transfection by combining permeabilization
of primary cells with a mild detergent, by association of
pDNA with a polycationic (poly-L-lysine) core covalently linked
to a receptor-ligand (transferrin) and addition of cationic
liposomes (Goomer et al., 2001). Transfection efficiencies using
lipofection reached 40% after 36 h (Stöve et al., 2002). Gene
delivery for tissue, which is rich in GAGs, collagens, and other
extracellular matrices (ECM) components seems particularly
challenging for in vivo delivery of DNA. Noteworthy, non-viral
gene delivery with FITC-labeled chondrocyte-affinity peptide
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(CAP) conjugated PEI/DNA particles was investigated in a
rabbit knee joint OA-model (Pi et al., 2011). These authors
found that by using the CAP-motive that the integration of
the PEI/DNA was much more efficient than with placebo.
Many more studies were undertaken based on in vitro
primary cultures (Odabas et al., 2013; Raftery et al., 2016)
using rabbit or bovine-derived chondrocytes or even patient-
derived chondrocytes. Recently, chondrogenic differentiation
was induced from induced pluripotent stem cells (iPSC) using
non-viral mini-circle vectors (Rim et al., 2020). The various
approaches for cartilage repair to treat rhematoid arthritis (RA)
were recently summarized by Pirmardvand Chegini et al. (2018).
Here, mainly anti-inflammatory genes like IL-1, IL-6, and IL-
10 were influenced by vector transfer. A prominent inducer for
the regeneration of cartilage, i.e., SOX9, delivered in non-viral
approach has been shown as a promising strategy (Song and Park,
2020). Also, here a wide range of studies used liposome-based
methods to transfect primary chondrocytes and MSCs (Goomer
et al., 2001; Stöve et al., 2002; Sun et al., 2009).
Synthetic Polymer-Based Gene Vectors
for Cartilage Repair
Recently, Gonzalez-Fernandez et al. (2017) found that if MSCs
were transfected with different gene carriers that the morphology
of MSCs was highly influenced by the application of different
categories of vectors. Generally, studies tried to modulate
and activate gene expression of differentiated chondrocytes
and/or MSCs. Target genes of interest were SOX9 and collagen
type X among others. It was shown that gold-nanoparticles
were found to be very efficient to transfer genes to cartilage
(Pirmardvand Chegini et al., 2018).
Physical Gene Vector Methods for
Cartilage Repair
Nucleofection through electroporation (EP) has been applied
successfully on primary chondrocytes in a high throughput
format (Haag et al., 2009). Earlier electroporation has been
evaluated in cartilage by Mir et al. (2005) among other tissues
to test regenerative effects in cartilage. A more systematic
comparison to address whether local administration versus
systemic gene electrotransfer (ET) could be more successful
would be to apply anti-inflammatory plasmids (Khoury et al.,
2006). They found in a mouse OA-model that intra-muscular
application of ET was more efficient than intra-articular ET,
which is unexpected, given the local administration of the vector
to the site of action.
Exosomes/Extracellular Vesicles for
Cartilage Repair
Extracellular vesicles were used successfully to thrive
differentiation of MSCs toward chondrocytes in vitro and in vivo
(see also chapter on EVs) (To et al., 2020). It has been shown
that cell-derived EVs are involved in the pathogenesis of OA,
playing important roles in antigen presentation, inflammation,
angiogenesis, cell–cell signal communication, thrombosis, and
articular cartilage ECM degradation (Fu et al., 2018; Rilla et al.,
2019). It could be shown that even up-regulation of autophagy is
involved in the release of EVs in bovine and human degenerated
chondrocytes (Rosenthal et al., 2015). It also has been shown
that their specific interactions exist between the ECM proteins of
articular cartilage and matrix EV’s proteins (Wu et al., 1992). In
chondrocytes (but also for osteoblasts and tenocytes) EVs play
a key role in the induction of matrix mineralization, these are
called matrix vesicles (MVs) (Anderson, 2003). Thus, MVs are
involved in the onset of calcification in painful OA-joints (Jubeck
et al., 2008). Chondrocytes have been proven in vitro to transfer
EVs to MSCs in co-culture (Kim et al., 2019). On the other hand,
EVs from MSCs activate chondrocytes and lead to an improved
ECM (Kim et al., 2019). It was further shown experimentally
that cellular proximity was needed to induce EV-associated
regenerative effects. Thus, EVs seem to be the perfect vehicle
to transfer DNA or RNA as these have been proven to exist
naturally, and some do even contain miRNA (Lin et al., 2018).
Summary of Non-viral Gene Delivery for
Cartilage Repair
To summarize, there were many studies conducted in the
area of cartilage repair (∼700 in PubMed, starting from 1986
to the present). Unsolved issues concern how EVs interact
with components of the ECM of cartilage. It seems clear that
hyaluronic acid (HA) and GAGs, such as chondroitin sulfate,
are involved in the regulation of EVs and MVs activity (Rilla
et al., 2019). Of great interest in the field of cartilage repair
is the ability of EVs to transfer bioactive cargo between cells
and influence phenotype and behavior directly upon uptake
(Gerlach and Griffin, 2016). The EV-mediated delivery of active
contents, including cytoplasmic and membrane proteins as well
as nucleic acids, and in particular miRNA sequences, has been
demonstrated (Gerlach and Griffin, 2016; Rilla et al., 2019).
Of specific interest is HA, which interacts via CD44 receptor,
and thus could be used as a potential non-viral gene delivery
system for chondrocytes. In vivo, particular challenges persist in
overcoming the barriers of GAG and other ECM components to
reach the chondrocytes with EVs or other non-viral vectors.
NON-VIRAL GENE DELIVERY TO THE
INTERVERTEBRAL DISK
The IVD is the largest avascular and aneural organ in the human
body. It is a joint between adjacent vertebrae in the spinal
column and facilitates flexion, extension, and rotation of the
spine while relying on the diffusion of nutrients through the
cartilage endplate of the vertebral body (Urban et al., 2004;
Heuer et al., 2008). As a consequence of the avascular nature
of this tissue, the healthy mature disk is relatively acellular; few
cells existing within a dense ECM of proteoglycans and collagen
(Humzah and Soames, 1988). During aging and degeneration,
there is a decline in matrix biosynthesis and cellularity, together
with an increase in catabolism and inflammation resulting in a
loss of IVD structure/function (Antoniou et al., 1996; Le Maitre
et al., 2007). These changes create a hostile microenvironment
for regenerative strategies that focus on restoring structure and
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function to the joint while reducing the underlying mechanisms
of disease. This, together with logistical and regulatory challenges,
pose significant barriers to the success of therapeutic strategies
for the IVD, specifically: (i) the lack of continuous drug delivery
systems, (ii) reduced sustained cell viability in the hostile
microenvironment of the IVD or (iii) regulatory and safety
hurdles in the case of viral gene editing that permanently
integrates with host DNA which may cause off-target mutations.
Current biological strategies for disk repair to date have focused
on growth factors, anti-inflammatory drugs, stem cell therapy
(adult mesenchymal and iPSC) and viral gene delivery (Sakai
et al., 2006; Orozco et al., 2011; Gorth et al., 2014; Hodgkinson
et al., 2019) with limited long-term efficacy and safety due
to many of the barriers stated above. Non-viral gene delivery
strategies for treating the degenerate and painful IVD are
receiving increasing attention given their potential for sustained
effects on the innate IVD cell phenotype of interest in situ;
however, this is still an emerging field with relevant studies
discussed below, described in Table 2 and categorized based on
their mode of delivery.
Lipid-Based Gene Vectors for the
Intervertebral Disk
Lipid-based gene delivery systems were amongst the first non-
viral methods used to investigate the effects of gene transfection
on IVD cells. Morrey et al. (2008) screened several lipid-based
non-viral agents for gene delivery in human degenerative IVD
cells in vitro focusing on efficiency, safety, and optimal dose.
Out of the seventeen agents assessed, they identified “LT1”
as the most efficient and least toxic when compared to other
lipid-based agents. When culture medium without antibiotics,
buffers, and amino acids was used, including hyaluronidase
pre- and post-transfection, these changes to the transfection
protocol increased efficiency while maintaining viability. Yet,
when compared to the adenoviral associated gene delivery
controls, LT1 transfection was significantly less efficient than viral
delivery, warranting a need for further optimization of these
transfection methods.
Lipofectamine has been used to transfect nucleus pulposus
cells with either DNA plasmid vectors as well as small interfering
RNAs (siRNAs) in vitro. To determine the potential of siRNAs
to knockdown gene expression in nucleus pulposus cells
isolated from rats and human patients with scoliosis, these
cells were co-transfected with reporter luciferase plasmid Firefly
and its corresponding siRNA using lipofectamine (Kakutani
et al., 2006). The expression of Firefly luciferase was reduced
by 94.7 and 93.7% in rat and human nucleus pulposus
cells respectively. This demonstrates successful knockdown of
“Firefly luciferase” that was maintained for 2 weeks, however,
significant decreases in nucleus pulposus cell proliferation were
observed compared to the fibroblast control and inhibitory
effects of knockdown disappeared by 3 weeks. To investigate
the effect of siRNAs on silencing a relevant target associated
with disk degeneration, Sudo and Minami (2011) transfected
rabbit nucleus pulposus cells with Caspase 3 siRNA in vitro
and in vivo using lipofectamine or “invivofectamine” reagent
complex, respectively. Significant decreases in apoptosis in vitro
and suppression of degenerative changes as observed on MRI
and histologically were noted in vivo with non-viral delivery
of Caspase 3 siRNA. In addition to the non-viral delivery of
siRNAs, lipofectamine has been used in vitro to transfect ovine
nucleus pulposus cells with a plasmid vector containing human
telomerase reverse transcriptase (hTERT) to examine effects
on cellular lifespan (Chung et al., 2007). hTERT significantly
increased telomerase activity, lifespan, and collagen I and
II expression relative to vector controls, however, karyotype
instability suggested further studies are necessary to validate the
safety of this strategy.
Lipid-based vectors such as liposomes have been used
to transfect multiple siRNAs into cells in vitro and in vivo.
Transfection of liposomal siRNA for Caspase 3 and A Disintegrin
and Metalloproteinase with Thrombospondin motifs-5
(ADAMTS5) was first optimized in a human hepatocellular
carcinoma cell line in vitro followed by injection of Caspase
3 and ADAMTS5 siRNA alone or in synergy into a rabbit
IVD puncture model (Banala et al., 2019). The liposomal
siRNA formulations for Caspase 3, including the combined
synergy groups, were able to limit IVD degeneration in vivo
as demonstrated by MRI and histopathology with the limited
effect of ADAMTS5 siRNA treatment alone suggesting that the
ADAMTS5 siRNA was ineffective at suppressing ADAMTS5
expression. The studies described above highlight the potential
of lipid-based transfection and vector-based systems to deliver
genes and gene targets successfully to IVD cells in vitro
and in vivo, however, given the limitations associated with
transfection efficiency and the few gene targets that have been
assessed so far, warrants further optimization of these methods
with a diverse array of gene candidates.
Synthetic Polymer-Based Gene Vectors
for the Intervertebral Disk
Synthetic polymer-based gene vectors are attractive alternatives
for non-viral gene delivery when compared to viral vectors as
they demonstrate low immunogenicity, have tunable structural
and surface components, and can be synthesized on a large
scale at relatively low-cost (Pack et al., 2005). A limited number
of studies have explored the potential of such polymer-based
non-viral gene delivery systems to treat IVD cells in vitro
and in vivo. Feng et al. (2015) developed an elegant system
to therapeutically deliver pDNA by combining cationic block
polymers polyethyleneglycol (PEG)-block-poly (N-[N-(2-
aminoethyl)-2-aminoehtyl]aspartamide) [PEG-b-PAsp(DET)]
and poly(N-isopropylacrylamide)-block-PAsp(DET) [PNIPAM-
b-PAsp(DET)], which they termed “mixed polyplex micelles”
(MPMs). These MPMs demonstrated high resistance to nuclease
activity and protein absorption including significantly higher
gene transfection efficiency in nucleus pulposus cells when
compared with single block polymers [PEG-b-PAsp(DET)]
in vitro and in vivo. Furthermore, when MPMs were loaded
with heme oxygenase-1 (HO-1), an anti-oxidant and anti-
inflammatory, and used to treat nucleus pulposus cells
previously stimulated with IL-1β in vitro, decreases in matrix
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TABLE 2 | Summary of non-viral gene delivery for the intervertebral disk.
Chemical
Vector/System
Scaffold/matrice
or add-on
Wound type Animals/Cells Growth Factor
or Gene
DNA/RNA Results References
Lipid-based transfection/Lipid-based gene vectors
LTI and other Lipid
based non-viral
reagents
N.D. In vitro Human IVD Cells Luciferase pDNA LT1 found to be lease toxic our of other lipid
based agents, but significantly less efficient
compared to Adeno = viral controls. Addition of
Hyaluronidase may increase transfection
efficiency.
Morrey et al., 2008
Lipofectamine 2000 N.D. In vitro Human and Rat Nucleus
Pulposus Cells
Firefly Luciferase pDNA and
siRNA
Reduction of Firefly luciferase in both rat and
human nucleus pulposus cells for two weeks
but the disappearance of inhibitory effects by
three weeks and a significant decrease in
cellular proliferation compared to fibroblast
controls.
Kakutani et al., 2006
Lipofectamine and
Invivofectamine
N.D. In vitro and
in vivo
Rabbit Nucleus Pulposus
Cells and annular puncture
model
Caspase 3 siRNA Decreased cell apoptosis in vitro with
suppression of degeneration in vivo.
Sudo and Minami, 2011
Lipofectamine N.D. In vitro Ovine Nucleus Pulposus
Cells
hTERT pDNA Increased telomerase activity, cellular lifespan,
and collagen I and II Production. However,
karyotypic instability warrants method safety.
Chung et al., 2007
Liposomes N.D. In vivo Rabbit IVD Puncture ADAMTS5 and
Caspase 3
siRNA Caspase 3 siRNA and in synergy with
ADAMTS5 siRNA limited disk degeneration.
However, ADAMTS5 siRNA alone was
ineffective in suppressing ADAMTS5.
expression
Banala et al., 2019
Synthetic polymer-based transfections/Synthetic polymer-based gene vectors
Mixed polyplex
micelles
PEG-poly(N-
isopropyl
acrylamide Mixture
In vitro and
in vivo
Rabbit Nucleus pulposus
cells and Rat Tail
degeneration Model
OH-1 pDNA High nuclease activity resistance, protein
absorption, and increase gene transfection
efficiency compared to single bock polymer
in vitro. OH-1 delivery decreased MMP3 and
COX-2 expression in vitro with an effective
decrease in inflammation and GAG restoration
in vivo compared to unique block polymer.
Feng et al., 2015
Nano polyplexes Polyplexes
encapsulated in
nano-spheres
In vivo Rat Tail degeneration Model NR4A1 pDNA Successful delivery of NR4A1 along with limiting
fibrosis.
Feng et al., 2017
(Continued)
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TABLE 2 | Continued
Chemical
Vector/System
Scaffold/matrice
or add-on
Wound type Animals/Cells Growth Factor
or Gene
DNA/RNA Results References
Synthetic polymer-based transfections/Synthetic polymer-based gene vectors
Injectable MMP
degradable
hydrogel
MMP responsive
polyplex micelles
In vitro and
in vivo
Rabbit Nucleus pulposus
cells and Intervertebral Disc
Puncture
miRNA-29 miRNA MMP-responsive polyplex micelles increased
the efficiency of cellular uptake and endosomal
escape. Limited fibrosus and reduce disc
degeneration in rabbit model.
Feng et al., 2018
Physical transfection methods / Physical gene vectors methods
Nucleofector
System Bulk
Electroporation
PEG Hydrogel
suspension for
organ culture
In vitro Human MSCs and Bovine
papain digest IVD organ
culture
GDF5 pDNA GDF5 expressed in monolayer cell culture up to
three weeks up-regulated ACAN, SOX9, KRT19
in transfected cells in a 3D alginate culture.
Partial GAG/DNA recovery at 7 days in organ
culture.
Bucher et al., 2013
Neon Transfection
System Bulk
Electroporation
N.D. In vitro Bovine and human IVD
Cells
pCMV6 pDNA Determined optimal electroporation parameters
for delivery into human and bovine IVD cells to
be two pulses at 1400 Volts for 20 ms.
May et al., 2017
Neon Transfection
System Bulk
Electroporation
N.D. In vitro Human Nucleus Pulposus
cells
Brachyury pDNA Significant increase in Brachyury, phenotypic
markers, decreased
inflammatory/catabolic/pain markers, and
increased GAG accumulation over four weeks.
Tang W. et al., 2019
Microbubble-
Enhanced
Ultrasound
N.D. In vivo Rat Tail IVD GFP and Firefly
Luciferase
pDNA Ultrasound transfection significantly enhanced
pDNA transfection efficiency into nucleus
pulposus cells in vivo—transgene expression
up to 24 weeks in IVD but declined with time.
Nishida et al., 2006
Exosomes/Extracellular Vesicles
MSC derived
exosomes
N.D. In vitro and
in vivo
Human Nucleus pulposus
cells and rattail IVD model
miRNA-21 miRNA MSC derived exosomes inhibited apoptotic
processes PTEN restraints in cells and
alleviates nucleus pulposus apoptosis and IVD
degeneration in vivo.
Cheng et al., 2018
N.D., non determined.
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metalloproteinase 3 (MMP3) and cyclo-oxygenase-2 (COX-
2) were observed. These effects were reproduced in an IVD
degeneration rat tail model where MPMs loaded with HO-1
were more effective an decreasing the inflammatory response
and restoring glycosaminoglycans (GAG) when compared
to the single block polymer loaded vectors. The authors of
this study went on to develop new synthetic polymer-based
non-viral gene delivery systems for treating IVD degeneration.
One involved nano-sized polyplexes that self-assemble into
a double-shell structure, which are then encapsulated in
biodegradable nano-spheres and co-injected with nanofibrous
spongy microspheres, providing a two-stage delivery system with
both temporal control and highly efficient delivery of pDNA
(Feng et al., 2017). This system was used to successfully deliver
the gene encoding anti-fibrotic agent, orphan nuclear receptor
4A1 (NR4A1) to the IVD in vivo, and limit fibrosis in a rat
tail model of disk degeneration. In a more recent study, Feng
et al. (2018) developed an injectable MMP-degradable hydrogel
encapsulating MMP-responsive polyplex micelles for continuous
and bioresponsive delivery microRNA-29 to limit fibrosis and
reduce degeneration in an in vivo rabbit puncture model of IVD
degeneration. These polyplex non-viral systems described above
highlight the potential of synthetic polymers to successfully
deliver genes of interest to the degenerate IVD using a variety
of small animal models (rat and rabbit) and gene targets with
high efficiency and low cytotoxicity. The next steps could include
longer-term studies (>12 months) and scaling-up to relevant
larger animal models of IVD degeneration such as the sheep,
goat, or dog.
Physical Gene Vector Methods for the
Intervertebral Disk
Physical methods for non-viral gene delivery offer a safe and
feasible way for transfecting large quantities of cells in vitro.
Studies by Bucher et al. used Nucleofector technology to
electroporate human MSCs with growth factor differentiation
factor 5 (GDF5) to transplant these cells in a degenerate bovine
IVD organ culture model (Bucher et al., 2013). Monolayer
cultures of transfected MSCs expressed GDF5 for up to
3 weeks. When GDF5 transfected MSCs were seeded in
alginate beads, key IVD markers ACAN, SOX9, and KRT19
were up-regulated in these cells compared to untransfected
cells. When GDF5 transfected MSCs were injected within a
PEG hydrogel suspension into the bovine IVD organ culture
papain degeneration model, a partial recovery of GAG/DNA
was observed after seven days. In a more recent study,
May et al. (2017) have used the Neon transfection system
to validate parameters of voltage, number and duration of
pulses for electroporation mediated gene transfer in bovine
and human IVD cells. They determined successful transfection
(≥47% efficiency) of commercially available plasmid pCMV6-
AC-GFP by flow cytometry with a protocol of two pulses
of 1400V for 20ms in bovine and human nucleus pulposus
and annulus fibrosus cells. The effect of transfecting GDF6
was examined using this protocol and system; however, due
to potential limitations with the specific GDF6 plasmid used,
no increase in ECM proteins could be observed. Tang et al.
used this same Neon transfection system to examine the effect
of electroporating developmental transcription factor Brachyury
into human nucleus pulposus cells from cadavers and patients
undergoing surgery for low back pain in 3D in vitro culture (Tang
S. et al., 2019). In this study, significant increases in Brachyury
were observed up to 4 weeks, together with improvements in IVD
phenotypic markers FOXF1, KRT19, and SOX9 and decreases
in inflammatory/catabolic/pain markers IL1−β, IL-6, NGF, and
MMP-13 compared to transfected sham vector control cells.
Besides, significant increases in glycosaminoglycan accumulation
were observed, suggesting that Brachyury was able to reprogram
degenerate nucleus pulposus cells to a healthier pro-anabolic
phenotype, however, since some effects appeared transient,
further optimization of the protocol was deemed necessary.
The studies described above highlight the potential and
feasibility of using bulk electroporation to deliver genes to
IVD cells non-virally. An alternative physical method that has
been investigated is Microbubble-Enhanced Ultrasound Gene
Therapy. GFP and firefly luciferase reporter plasmids were
mixed with microbubbles of ultrasonography contrast agent and
injected into the IVDs of rat tails in vivo (Nishida et al., 2006).
Therapeutic ultrasound was applied to the surface of inserted
disks, and the IVD was isolated at 1, 3, 6, 12, and 24 weeks post-
injection. Transgene expression was observed up to 24 weeks
in the IVD however, overall declined with time suggesting that,
while a potentially promising method, further validation of this
technique may be necessary.
Physical non-viral transfection of pDNA is an attractive
method for delivering genes of interest to the IVD.
Electroporation shows promise for in vitro gene delivery,
however, a direct translation of this method for use in vivo
in relevant animal models of disk degeneration is more
challenging, and this is where other physical techniques such as
ultrasound could be used.
Exosomes/Extracellular Vesicles for the
Intervertebral Disk
The therapeutic potential of exosomes and EVs is a new and
emerging field. With respect to the IVD, exosomes derived from
both human MSCs and nucleus pulposus cells have been shown
to promote ECM biosynthesis and enhance IVD phenotypic
markers when co-cultured with either nucleus pulposus cells or
MSCs, respectively (Lu et al., 2017). A recent study by Cheng et al.
(2018) has demonstrated the potential of MSC derived exosomes
to deliver specific endogenous cargo in the form of microRNAs
to nucleus pulposus cells in vitro and in vivo suggesting that
exosomes could be engineered to deliver specific exogenous
pDNA to IVD cells as a method of non-viral gene delivery.
Summary of Non-viral Delivery Systems
for the Intervertebral Disk
Identifying non-viral gene delivery systems for the treatment of
IVD degeneration is a research priority given the potential of gene
therapy-based approaches to regenerate the IVD using discogenic
growth factors, RNA interference/silencing and transcription
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factors and limitations associated with the use of viral vectors.
While this is still a growing area for the IVD, the studies
described above highlight the clinical applicability and relevance
of these methods as safe and efficacious alternatives to viruses that
warrant further investigation.
NON-VIRAL GENE DELIVERY TO BONE
Bone tissue has the ability to repair and regenerate itself.
Nonetheless, this capacity may be reduced or completely lost
depending on the size of the defect (aka. critical size defect) or
by the presence of specific disease states. They were going further
from a healthy state of bone tissue results in clinical cases with
an increase in morbidity and mortality (Vajgel et al., 2014). In
this context, bone grafts are widely applied in a wide array of
clinical settings to augment or induce bone regeneration and
repair. Therapies currently used, such as allografts and autografts,
involve numerous practical and clinical problems.
On the one hand, allografts have enhanced osteoinductivity
and are relatively abundant in supply; nevertheless, they involve
the potential risk to transmit disease. On the other hand,
autografts are still considered as the “gold standard” for bone
regeneration, as they can provide all the needed osteogenic
components for bone repair. However, pain and morbidity
at the donor site, a limited amount of available tissue, but
also prolonged surgery are the main problems now facing
this clinical approach. Nowadays, besides bone autografts and
allografts, regenerative procedures are more focused on bone
tissue engineering as an alternative using ceramics, polymers,
and growth factors (Dimitriou et al., 2011). In combination with
those scaffolds and biomaterials, factors inducing osteogenesis
have been used to accelerate bone healing (Pereira et al., 2020).
Many teams designed excellent delivery systems for growth
factors; however, recombinant growth factors are expensive and
onerous to produce (De Witte et al., 2018). Moreover, in an
in vivo setting, high doses must be injected/administered to
address the issues related to the brief half-life of the growth
factors (Balmayor and van Griensven, 2015). In summary, we
can say that protein delivery systems are still paved with many
challenges, while gene therapy may provide a more suitable
alternative.
Non-viral gene delivery/transfer is often performed using
pDNA These circular, small, double-stranded DNA structures are
stable, can be readily produced in bacteria and customized with a
variety of different promoters (Gill et al., 2009). To be transcribed
by the recipient cell, the pDNA has to reach the cell’s nucleus,
and several barriers have to be overcome for this to occur. First
of all, body clearance (in vivo) and degradation must be limited.
Secondly, to be efficient, the pDNA has to cross both cell and
nuclear membranes to enter the nucleus. Thirdly, the pDNA has
to be released from any possible transfection complexes (Dang
and Leong, 2006; Smith, 2008). To be efficient, a non-viral gene
delivery is dependent on; (I) the DNA sequence, (II) preparation
of the construct, (III) purification from bacterial expansion, (IV)
the chosen transfection method, (V) the recipient cell type, and
(VI) the cell cycle phase the recipient cells are in Table 3.
To deliver biologics to the bone fracture site to repair bone
defects, gene therapy using gene vectors offers an attractive
alternative method. At the delivery site, the target genes induce
the production of potent growth factors (e.g., endogenous
BMPs, VEGF) (Curtin et al., 2015), which is more efficient
than exogenous delivery of recombinant proteins. Additionally,
gene therapy induces in situ osteoblast differentiation, enhances
osteoinduction via the expression of growth factors, and
facilitates mineralized matrix production (Luo et al., 2005).
Recently, non-viral gene delivery vectors, including lipids,
peptides, dendrimers, and cationic polymers have been proposed
as alternative strategies for gene delivery. This renewed interest is
mainly attributed to their many advantages, such as the absence
of endogenous virus recombination, their low immunogenicity,
and tunable construction and easy fabrication (Pack et al., 2005;
Mintzer and Simanek, 2009; Guo and Huang, 2012). Futhermore,
many of these non-viral gene vectors have been used in clinical
trials, combined with or without biomaterials (Li et al., 2016). In
the following section, we summarize the most commonly used
non-viral gene vectors and highlight their potential applications
(Lechardeur and Lukacs, 2002; Ramamoorth and Narvekar, 2015)
or more advanced ones (Pack et al., 2005; Mintzer and Simanek,
2009; Guo and Huang, 2012).
Lipid-Based Gene Vectors for Bone
The most commonly used lipid-based delivery systems, e.g.,
FuGENETM and Lipofactamine 2000TM, have been widely used in
research for several years due to their high and stable transfection
efficiencies and commercially availability. On one hand, we
can notably cite FuGENE6, which was used to transfer the
gene TGF-β1, an osteoinductive growth factor into osteoblasts
(Macdonald et al., 2007). After transfection, the osteoblasts
demonstrated superior cell proliferation in comparison to cells
treated with equivalent levels of recombinant TGF-β1 added to
the culture medium. These results highlighted the advantages
and efficiency of gene delivery instead of exogenous delivery of
growth factors for bone tissue engineering (Macdonald et al.,
2007). Lipofectamine 2000-based formulations have been used
to deliver the oligonucleotide antimiR-138 to bone-marrow
derived stromal cells (BMSCs) to form stem cell “patches.”
When these sheets are applied to freeze-dried allograft bone,
this induces massive bone regeneration with good vascularisation
(Yan et al., 2014). Another example of lipid-based non-viral
gene delivery system are the two molecules 1,2-dioleoyl-3-
trimethylammonium propane (DOTAP)-2-dioleoyl-sn-glycerol-
3-phosphatidylethanolamine and DOTAP-cholesterol. These
two were used to deliver β-galactosidase plasmid to human
and mouse osteoblastic cell lines (MG63 and MC3T3-E1,
respectively). To increase the expression and efficiency of this
delivery system, transferrin was incorporated into the system.
The results demonstrated that this method had a higher efficiency
in osteoblastic cell lines than in a human melanoma cell
line (aka. 294T cell line). It also revealed a high correlation
between lipid formulation, transfection activity, DNA dose,
and charge ratios of the complexes (Oliveira et al., 2009;
Yan et al., 2014).
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Lipid-mediated gene transfer was one of the earliest strategies
applied in gene therapy (Dwivedi et al., 2012), and positively
charged liposomes were the first non-viral delivery vectors used
in clinical trials (Li et al., 2015). Most of the time, to initiate
bone progenitor cell differentiation and newly formed bone
ossification, strategies have been focused on the delivery of genes
encoding TGF-β and BMPs (Winn et al., 2005; Guo-ping et al.,
2010). Another approach can be to target directly the master gene
of bone differentiation (aka. runt-related transcription factor
2, RUNX2) with DNA plasmid encoding transcription factor
RUNX2 loaded into liposomes and covalently immobilized onto
polycaprolactone (PCL) nanofibers (Monteiro et al., 2014). Using
BMSCs results showed that cells cultured with this setup showed
a higher total protein synthesis and enhanced levels of metabolic
activity (Table 3). However, even though liposome-based gene
delivery was one of the first methods used to introduce exogenous
DNA into eukaryotic cells, this method is not widespread in
other fields like bone tissue engineering. This is possibly due
to the involvement of cationic liposomes (lipoplexes), which
are cytotoxic at higher concentrations (Tachibana et al., 2002;
Madeira et al., 2010). For this reason, liposomes associated with
scaffolds as a combined system should be used to deliver genes in
a cell-controlled and spatially localized manner, for efficient bone
tissue engineering applications.
Synthetic Polymer-Based Gene Vectors
for Bone
Synthetic polymers can be also used as non-viral gene carriers
as they can be endocytosed by cells. A variety of molecules that
can differ in chemical composition, 3D architecture, weight, side-
chain length, size, and branching, or even density, are available
(Park et al., 2006). Most polymers described in the literature for
gene therapy are cationic (aka. with a positive charge) with mainly
amines groups (Santos et al., 2011). These positive groups interact
with the negatively charged phosphate groups present in the
DNA sequence and after association form condensed structures
called polyplexes.
PEI, one of the first and most successful polyplexes used as
non-viral gene vectors (Pack et al., 2005), was first introduced
in 1995 both in vitro and in vivo (Boussif et al., 1995). PEI
as a non-viral vector has several critical advantages over viral
vectors; (I) it is less cytotoxic, (II) less immunogenic, (III) there
are no carcinogenic concerns, (IV) it induces transient gene
expression, and (V) it is safe for clinical use (Pack et al., 2005).
Additionally, PEI has a high transfer efficiency (Akinc et al., 2005;
Deng et al., 2009; Schafer et al., 2010) due to a phenomenon
known as “proton sponge effect” (Benjaminsen et al., 2013).
The transfection efficiencies are comparable with viral gene
delivery agents (Abdallah et al., 1996). Numerous publications
have highlighted the branched 25 kDa PEI polymer as the most
widely utilized gene transfer agent (Huang et al., 2005a,b; Ali and
Mooney, 2008) and as a “gold standard” (aka. positive control)
across in vitro studies (Park, 2009). In brief, PEI combined with
pDNA as polyplex have properties that can be changed by merely
altering the PEI amines/DNA phosphates ratio. Higher ratios of
PEI to pDNA usually result in higher transfection efficiencies,
but the downside is an increased cytotoxicity (Boussif et al.,
1995; Godbey et al., 1999). To optimize the use of polyplexes
for gene transfer for bone tissue engineering applications, a
balance between efficiency and cytotoxicity must be reached
(Tierney et al., 2012).
To achieve the above, collagen scaffolds can be used to
incorporate the complex branched PEI (25 kDa) with pDNA
(Elangovan et al., 2014). The use of gene-activated scaffolds (with
pPDGF-β) in a calvarial defect rat model, favored cell attachment
and promoted cell proliferation in vitro. It was also described
to promote osteogenesis (osteoinduction and osteoconduction)
and demonstrated superior tissue regeneration when compared
to empty scaffold and empty calvarial defect groups. Another
documented polyplex is the combination of PEI (branched,
25 kDa)/pBMP-2, in association with a poly(ε-caprolactone)
scaffold. This combination was applied to initiate in vitro
differentiation of myoblasts (Reckhenrich et al., 2012). With
optimized gene doses, cells increased the secretion of osteocalcin
and osteopontin compared to the control group, demonstrating
transdifferentiation of C2C12 cells into the osteoblastic lineage.
As a last example of polyplex, we can cite the advanced system
consisting of dural plasmids, polyethyleneglycol (PEG)-block-
catiomer (PEG-b-P[Asp-(DET)]) and a CaP-cement scaffold.
This system has a high bio-compatibility rate with plasmids
encoding osteogenic factors, activin receptor-like kinase 6
(caALK6) together with RUNX2 (Itaka et al., 2007). With
this delivery system, osteogenic differentiation was enhanced
compared to PEI or FuGENE6 (Itaka et al., 2007). Another study
used branched PEI (25 KDa) with siRNA or miRNA to create
complexes encapsulated within the PEG hydrogel, to deliver
nucleic acids directly in situ. The goals of this study were to guide
stem cells through osteogenic lineage with localized and sustained
RNA release (Nguyen et al., 2014).
Natural Polymer-Based Gene Vectors for
Bone
Natural polymers have been used due to their lower cytotoxicity
and enhanced biocompatibility compared to synthetic polymers.
Chitosan is one of the most studied natural polymers in bone
tissue engineering (Raftery et al., 2013). Biodegradable and
biocompatible, chitosan is formed by deacetylating chitin and
can be used as a gel or as micro/nanoparticles (Moreira et al.,
2009; Garcia-Fuentes and Alonso, 2012) to form complexes with
pDNA. Compared with liposomes, the transfection efficiency
of chitosan is always a little bit lower (comparable to naked
DNA), but it is significantly less toxic than liposomes and easy
to work with (Corsi et al., 2003). To overcome the problem of
lower transfection efficiencies, chitosan is combined with other
biomaterials. For orthopedic applications, it can be incorporated
into titanium films with pDNA for BMP-2 or even incorporated
in alginate hydrogel as nanoparticles (Park et al., 2007). In
addition to chitosan, alginate has also been utlized for gene
delivery. It has many advantages such as; (I) it is non-toxic, (II)
bacteriostatic, (III) anti-inflammatory, (IV) biocompatible, and
(V) form of nanoparticles or be combined with other hydrogels
(Krebs et al., 2010). The use of alginate-mediated transfections
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TABLE 3 | Summary of non-viral gene delivery vector applied to bone tissue engineering.
Chemical vector Scaffold/matrice or
add-on
Wound type Animal; Cells Growth
Factor or else
DNA/RNA Results References
Lipid-based transfection / Lipid-based gene vectors
FuGENE 6 N.D. in vitro Fetal Rat Osteoblasts TGF-β1 pDNA Higher cell proliferation compared
recombinant TGF-β1 delivery in the
medium.
Macdonald et al.,
2007
Lipofectamine 2000 N.D. in vitro BMSCs antimiR-138 Oligonucleotide Massive bone regeneration and with
good vascularisation were achieved.
Yan et al., 2014
(DOTAP)-2-dioleoyl-sn-
glycero-3-
phosphatidylethanolamine
Transferrin in vitro MG63 and MC3T3-E1
cells
β-galactosidase pDNA High correlation between lipid
formulation and transfection activity.
Oliveira et al., 2009
Cationic
liposome-based
reagent
N.D. in vitro Human BMSCs GFP pDNA High viabilities and recoveries of the
transfected cells as well as
multipotency.
Madeira et al., 2010
Cationic liposome N.D. in vitro AH130 cells N.D. pDNA Efficient transgene expression as well
as enhanced nuclear delivery.
Tachibana et al.,
2002
DODAP, HSPC, Chol,
and DSPE-PEG
Polycaprolactone (PCL)
scaffolds
in vitro Human BMSCs Runx2 pDNA Osteogenic differentiation was achieved
with long-term gene expression of
RUNX2.
Monteiro et al.,
2014
FuGENE 6 Type-I collagen and
poly(lactide-co-glycolide)
(PLG) scaffolds
in vitro BHK cells N.D. pDNA Improvement of the functional stability
and release duration.
Winn et al., 2005
Lipofectamine N.D. in vitro Human BMSCs BMP-2 and
VEGF165
pDNA Differentiation abilities of BMSCs were
enhanced.
Guo-ping et al.,
2010
Amaxa Nucleofector- II N.D. in vitro Human primary
calvarial suture MSCs
BMP-2 and
BMP-3
pDNA Efficient, a non-viral alternative method
for in vitro applications.
Dwivedi et al., 2012
Synthetic polymer-based transfections / Synthetic polymer-based gene vectors
Polyethylenimine (PEI) N.D. Intracerebral
transfer
primary rat brain
endothelial cells or
chicken embryonic
neurons.
Luciferase pDNA Results comparable or even better than
lipopolyamines.
Boussif et al., 1995
Polyethylenimine (PEI) N.D. N.D. COS-7 cells Luciferase pDNA Transfection activity of PEI vectors is
due to their unique ability to avoid
acidic lysosomes.
Akinc et al., 2005
Polyethylenimines
(PEIs) with F25-LMW
Liposome
N.D. N.D. SKOV-3 cells N.D. pDNA and
siRNA
Lipopolyplexes show improved
biological properties over PEI
complexes
Schafer et al., 2010
Polyethylenimine
(PEI)-7K-L
N.D. N.D. 293T cells Luciferase pDNA PEI-7K-L is less cytotoxic and more
efficient than both PEI-25K and
Lipofectamine 2000 in the in vitro gene
transfection
Deng et al., 2009
(Continued)
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TABLE 3 | Continued
Chemical vector Scaffold/matrice or
add-on
Wound type Animal; Cells Growth
Factor or else
DNA/RNA Results References
Synthetic polymer-based transfections / Synthetic polymer-based gene vectors
Polyethylenimine (PEI) N.D. N.D. HeLa cells N.D. pDNA PEI cannot induce changes in
lysosomal pH.
Benjaminsen et al.,
2013
Polyethylenimine (PEI) N.D. Adult (eight weeks
old) OFl female or
male mice central
nervous system /
neural disorder
Neuronal cultures Luciferase and
bcl2
pDNA PEI appears to have potential for
fundamental research and genetic
therapy of the brain.
Abdallah et al.,
1996
Polyethylenimine (PEI) N.D. N.D. Dendritic cells GM-CSF pDNA Results open new approches for novel
delivery vectors for in situ vaccination
and the treatment of autoimmunity.
Ali and Mooney,
2008
Polyethylenimine (PEI) Porous
poly(lactide-co-glycolide)
(PLG) scaffolds
Subcutaneous
implantation
Rat β-galactosidase pDNA In vivo long-term and high level of gene
expression.
Huang et al., 2005a
Polyethylenimine (PEI) Poly(lactic-co-glycolic acid)
(PLGA) scaffolds
Calvarial defects Rat BMP-4 pDNA PEI scaffold delivery system was able to
enhance bone formation.
Huang et al., 2005b
Polyethylenimine (PEI) Collagen, collagen GAG,
and collagen nHa scaffolds
N.D. Rat MSCs Luciferase pDNA PEI is a highly efficient pDNA
transfection agent for both MSC
monolayer cultures and 3D
environment.
Tierney et al., 2012
Polyethylenimine (PEI) Collagen scaffolds Calvarial defects Rat; Human BMSCs PDGF-B pDNA PDGF-B gene-activated scaffolds are
useful for bone regeneration.
Elangovan et al.,
2014
Polyethylenimine (PEI) Poly-(ε-caprolactone)
scaffolds
N.D. C2C12 cells BMP-2 pDNA PEI, as bioactive implant surfaces give
rise to promising results.
Reckhenrich et al.,
2012
Poly(ethyleneglycol)
(PEG)
N.D. Calvarial defects Mice; Mouse calvarial
cells
caALK6 and
Runx2
pDNA First, in vivo gene transfer with
therapeutic potential using polyplex
nanomicelles.
Itaka et al., 2007
Poly(ethyleneglycol)
(PEG)
Poly(ethylene glycol) (PEG)
hydrogels
N.D. HEK293 cells and
Human MSCs
GFP and
Luciferase
siRNA Delivery of siRNA and miRNA from the
hydrogel constructs enhanced the
osteogenic differentiation.
Nguyen et al., 2014
Natural polymer-based transfection / Natural polymer-based gene vectors
Chitosan functionalized
with imidazole moieties
N.D. N.D. 293T and HepG2 cells β-galactosidase pDNA Enhanced β-gal expression. Moreira et al., 2009
Calcium phosphate Chitosan Subcutaneous
implantation
Mice; MC3T3-E1 cells BMP-2 pDNA Bone tissue formation in vivo after
implantation.
Krebs et al., 2010
Alginate hydrogel N.D. ? Mice; Human MSCs
and MG-63 cells
BMP-2 pDNA Alginate hydrogel seems to be highly
suitable for the delivery of growth
factors in bone regeneration.
Wegman et al.,
2011
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TABLE 3 | Continued
Chemical vector Scaffold/matrice or
add-on
Wound type Animal; Cells Growth
Factor or else
DNA/RNA Results References
Natural polymer-based transfection / Natural polymer-based gene vectors
Alginate hydrogel Ceramic granules Spinal cassettes Goat MSCs BMP-2 pDNA Alginate hydrogel led to stable
expression of BMP-2 and promoted
osteogenic differentiation.
Wegman et al.,
2014
Chitosan N.D. N.D. Human MSCs, MG63,
and HEK293 cells
β-galactosidase pDNA Chitosan-DNA nanoparticles are cell
type-dependent and not cytotoxic.
Corsi et al., 2003
Chitosan-alginate N.D. Subcutaneous
implantation
Mice; HEK 293 cells
and Human MSCs
BMP-7 pDNA The chitosan-alginate gel used a gene
delivery system seems to be an exciting
approach for tissue engineering.
Park et al., 2007
Composites of
cationized gelatin
microspheres (CGMS)
Oligo(poly(ethylene
glycol)fumarate) (OPF)
Subcutaneous
implantation
Mice BMP-2 pDNA Composites can prolong and control
the release of pDNA.
Kasper et al., 2005
Composites of
cationized gelatin
microspheres (CGMS)
Oligo(poly(ethylene
glycol)fumarate) (OPF)
Calvarial defects Rat BMP-2 pDNA The release of plasmid DNA from the
composites was not sufficient to induce
bone repair.
Kasper et al., 2006
Branched
triacrylate/amine
polycationic polymer
with gelatin
microparticles
Oligo(poly(ethylene
glycol)fumarate) (OPF)
Calvarial defects Rat; CRL 1764 cells BMP-2 pDNA Polycationic polymers with a slow
degradation rate can prolong the
release of pDNA.
Chew et al., 2011
Alginate hydrogel Hyaluronic Acid (HA)-based
Gel
Tibial defects Rabbit TGF-β1 and
FGF-2
proteins By angiogenesis inhibition and hypoxic
environment promotion, cartilage
formation can be exclusively promoted.
Stevens et al., 2005
Inorganic nanoparticles transfection / Inorganic nanoparticles gene vectors
Calcium phosphate
nanoparticles
N.D. N.D. HeLa and MC3T3-E1
cells
Luciferase pDNA Transfection efficiencies due to efficient
condensation and bound of pDNA.
Olton et al., 2007
Calcium phosphate
nanoparticles
Polyelectrolyte multilayer
poly-(L-lysine) (PLL)
N.D. Human osteoblasts Spp1 for the
silencing of
osteopontin
expression and
Bglap-rs1 for
silencing of
osteocalcin
expression
shRNA A multilayered films-based delivery
system containing nanoparticles for
gene silencing can specific for bone
cells.
Zhang et al., 2010
Hydroxyapatite
nanoparticles
Collagen scaffolds Calvarial defects Rat; MSCs, HUVECs,
MC3T3-E1s
BMP-2 and
VEGF-165
pDNA Bone regeneration was accelerated. Curtin et al., 2015
Alginate Ceramic granules Spinal cassettes Goat; Goat MSCs BMP-2 and
VEGF-165
pDNA Transfection from this DNA delivery
system led to a stable expression of
BMP-2 during 16 weeks.
Wegman et al.,
2014
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Chemical vector Scaffold/matrice or
add-on
Wound type Animal; Cells Growth
Factor or else
DNA/RNA Results References
Inorganic nanoparticles transfection / Inorganic nanoparticles gene vectors
Polyethylenimine
(PEI)-LA
Gelatin/collagen scaffolds Subcutaneous
implantation
Rat bFGF and
BMP-2
pDNA Scaffolds delivering complexes
influenced recombinant protein
production.
Rose et al., 2012
Lipofectamine 2000
(coprecipitated within
apatite)
PLGA films N.D. C3H10T1/2 cells β-galactosidase pDNA The hybrid material system integrates
conductivity provided by the apatite
and inductivity supplied by the DNA.
Luong et al., 2009
Physical transfection methods / Physical gene vectors methods
Electroporation HA/β-TCP scaffolds Calvarial and
long-bone
segmental defects
Rat; ASCs BMP-2 to
VEGF-165
pDNA Induction of rapid angiogenesis and
osteogenesis.
Lee et al., 2019
TransIT-2020 Matrigel Calvarial defects Rat; Rat BMSCs BMP-2 pDNA BMSCs transfected with BMP-2
provided better osteogenic
differentiation than primary BMSCs.
Hsieh et al., 2018
Sonoporation N.D. Ectopic
implantation - Mice;
Orthotropic
implantation – Rat
Mice and Rat BMP-2 and
BMP-7
pDNA Sonoporation increased callus
formation and heterotopic ossification.
Feichtinger et al.,
2014
Ex vivo transfections / Ex vivo gene vectors
NucleofectorTM Fibrin gel Coccygeal
vertebrae
Rat; Porcine ASCs BMP-6 pDNA ASCs modified with BMP-6 can repair
vertebral bone defects.
Sheyn et al., 2011
NucleofectorTM N.D. Spinal fusion in
lumbar
paravertebral
muscle
Mice; Porcine ASCs BMP-6 pDNA Formation of a large bone mass
adjacent to the lumbar area, which
produced posterior spinal fusion.
Sheyn et al., 2008b
Microporation
transfection
Poly(lactic-co-glycolic acid)
(PLGA) scaffolds
Dorsal
subcutaneous
spaces
Mice; Human ASCs BMP-2 and
Runx2
pDNA The co-transfection of two osteogenic
lineage-determining genes could
enhance osteogenic differentiation of
ASCs.
Lee et al., 2010
Lipofectamine 2000 N.D. Osteodistraction of
the mandible
Rabbit; Rabbit BMSCs Osterix pDNA Promotion of bone formation. Lai et al., 2011
(Continued)
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Chemical vector Scaffold/matrice or
add-on
Wound type Animal; Cells Growth
Factor or else
DNA/RNA Results References
Peptides
protease-degradable
(PEG) functionalized
with a peptide
(GFOGER)
N.D. Radius defects Mice; Human MSCs BMP-2 protein GFOGER hydrogels promote bone
regeneration with low delivered BMP-2
doses.
Shekaran et al.,
2014
(K)16GRGDSPC Bioactive bone
matricesPLGA-[ASP-PEG]n
Segmental bone
defects in femoral
shafts
Rabbit; Human BMSCs TGF-β1 pDNA The biomimetic bone matrix is a very
promising scaffold to increase of bone
repair.
Pan et al., 2014
Hybrid for transfections / Hybrid as gene vectors
Polyethylenimine
(PEI)-LA
Gelatine and collagen
scaffolds
Subcutaneous
implantation
Rat; 293T cells bFGF and
BMP-2
pDNA PEI-LA was effective in vivo gene
delivery carrier.
Rose et al., 2012
Organic/inorganic
hybrid co-precipitated
within apatite
PLGA films N.D. C3H10T1/2 cells β-galactosidase pDNA This hybrid material system integrates
inductivity provided by the DNA and
conductivity provided by the apatite.
Luong et al., 2009
Cationized gelatin
microspheres and OPF
N.D. N.D. N.D. N.D. pDNA In vivo prolongation of the availability of
pDNA.
Kasper et al., 2005
Cationized gelatin
microspheres within a
crosslinked OPF
N.D. Calvarial defects Rat BMP-2 pDNA The release of plasmid DNA from the
composites was not sufficient to elicit a
bone regeneration response.
Kasper et al., 2006
TAPP complexed with
gelatine microparticles
poly(propylene fumarate)
scaffolds
Calvarial defects Rat N.D. pDNA Slow degradation rate can prolong the
release of pDNA from the composite
scaffolds.
Chew et al., 2011
Chitosan-disulfide-
conjugated low
molecular weight PEI
N.D. N.D. MG-63 cells and stem
cells
BMP-2 pDNA Transfection efficiency was significantly
higher than PEI and comparable to
Lipofectamine.
Zhao et al., 2013
Others
Electrospinning Non-woven, nano-fibered,
PLGA, PLA-PEG
N.D. MC3T3-E1 cells β-galactosidase pDNA Incorporation of pDNA into a polymer
scaffold can be achieved using
electrospinning.
Luu et al., 2003
Polymer Matrices Porous
poly(lactide-co-glycolide)
(PLG) scaffolds
Subcutaneous
implantation
Rat; 293T cells PDGF pDNA Enhanced matrix deposition and blood
vessel formation.
Shea et al., 1999
Gene activated
matrices
Collagen I scaffolds Femoral and tibial
metaphysis defects
Dog PTH pDNA Induction new bone formation. Bonadio et al.,
1999
N.D., non determined.
Frontiers
in
B
ioengineering
and
B
iotechnology
|w
w
w
.frontiersin.org
23
N
ovem
ber
2020
|Volum
e
8
|A
rticle
598466
fbioe-08-598466 November 17, 2020 Time: 12:17 # 24
Gantenbein et al. Non-viral Gene Therapy for Bone and Joints
with pDNA was characterized by high transfection efficiency,
slow release kinetics, in vitro osteogenic differentiation, and
in vivo bone formation (Wegman et al., 2011, 2014). It has been
applied in bone tissue-engineering applications both in vitro
and in vivo (Bourgeat-Lami, 2002; Stevens et al., 2005). Gelatin
as another well-known natural polymer that has been widely
used in bone tissue engineering as a delivery system for DNA
and growth factors (Kasper et al., 2005; Kasper et al., 2006;
Chew et al., 2011). In general, natural polymers, are often easy
to work with, are readily available and rarely trigger immune
responses. Yet they are not widely utilized gene-delivery systems
for tissue engineering. Apart from polyplexes or lipoplexes,
these natural polymers are also often combined with other
materials such as ceramics or synthetic polymers to be closer to
biomechanical, osteoconductive, and osteoinductive properties
of the targeted tissue.
Inorganic Nanoparticles Gene Vectors
for Bone
New studies have demonstrated the use of inorganic
nanoparticles as a NVGD method (Bourgeat-Lami, 2002;
Chowdhury and Akaike, 2005). These methods consist mostly of
coupling small material particles such as iron oxide, silica, gold,
or even calcium phosphate (CaP) with plasmid DNA. These
particles deliver the pDNA into the cell via endocytosis. CaPs
particles are favored in bone regeneration for their capacity to
increase the strength and stiffness of the constructs. CaPs possess
numerous advantages, which include; (I) excellent stability, (II)
are biodegradable and biocompatible, (III) good solubility, (IV)
good resorbability, (V) good binding affinity to DNA, and (V)
efficient cellular uptake (Olton et al., 2007). CaPs present lower
toxicity than carbon nanotubes, silica, magnetic particles, or
quantum dots (Olton et al., 2007). CaP nanoparticles have also
been combined with shRNA (Olton et al., 2007). When applied to
human osteoblasts, this system showed efficient bone formation
(Olton et al., 2007). Related to CaPs and known as the mineral
component of bone Hydroxyapatite (HA) can also be used as a
component of the NVGD strategy (Uskokovic and Uskokovic,
2011). Another related example, the nanohydroxyapatite (nHA)
vector can deliver pDNA encoding for VEGF and BMP-2 to
MSCs, and as a result, can markedly enhance bone healing and
tissue vascularisation (Curtin et al., 2015). While these methods
demonstrate some limitations such as moderate transfection
efficiency and retention within the circulation, they do show
several advantages, such as; (I) easy storage ability, (II) low
toxicity, and (III) reasonable shape control. As a consequence,
more and more studies are utilizing inorganic nanoparticles
(Parveen et al., 2012).
Physical Gene Vector Methods for Bone
Physical transfection methods involve permeabilization of the
cell membrane, allowing pDNA to enter the cells. Different
methods are used to permeabilize the cell membrane “in a
safe way,” such as electroporation, which uses a high-intensity
electric pulse. This method is not very often used but can present
interesting results in the context of bone tissue engineering (Lee
et al., 2019). With a transfection efficiency reaching 70–75%,
BMP2 gene transduction using electroporation for the functional
enhancement has been shown to enhance the in vivo osteogenic
potential of human bone-marrow-derived mesenchymal stromal
cells (hBMSCs) and adipo-tissue-derived stromal cells (ASCs),
alone, or in combination with other factors (Hsieh et al., 2018).
Sonoporation disrupts the cell membrane using ultrasound to
induce transfection. However, this method is not very successful
and is considered as a highly experimental procedure since cell
death is high. To compensate for the lower efficacy of this
NVGD method, a highly osteoinductive co-expression strategy
was investigated using BMP 2 and BMP-7 with significant results
(Feichtinger et al., 2014) (Table 3). When sonoporation was
directly compared with passive gene delivery, it demonstrated
an increased probability of gene expression and bone formation
related to the ultrasound energy applied. However, bone-related
gene expression levels and bone volumes were not increased.
All physical methods, however, destabilize the cell membrane
temporarily, which in many cases leads to low cell survival.
The problem of those techniques is to search out the optimal
conditions. One more difficulty is to reach deep into the tissue.
These techniques are mainly capable of penetrating the skin and
might maybe reach the adipose tissue and muscle just under
the skin. However, bone cannot be reached with non-invasive
methods, making it less optimal for orthopedic applications.
Ex vivo Gene Vectors for Bone
For all the non-viral gene therapy technics/approaches described
above and applied in bone tissue engineering for bone
regeneration, many hurdles need to be overcome as most of
the techniques are based on particle uptake and controlled cell
membrane damage. After described the techniques above, we
can say that the main disadvantages of in vivo application are;
(I) low penetration depth, (II) high levels of cell death and
tissue damage, (III) chances of off-target effects, and (IV) risk of
particle migration. Doing ex vivo transfections could be one way
to overcome those issues. In that case, the DNA is not directly
transferred into the body to the cells of interest; however, in
a multiple steps protocol, the desired host cells are (I) isolated
from the body, (II) transfected in vitro followed by a selection,
and (III) and “grafts” back to the host to act as protein factories
or directly as bone-forming cells. The two main advantages
compared to in vivo transfections are the step pre-selection of
the cells of interest and the post-selection of the transfected cells.
This step of quality control of the used cells increases the safety
of this NVGD strategy. As safety is one of the main concerns
in bone regenerative medicine, the ex vivo NVGD model seems
to be more potent at the moment in the context of clinical
applications (Sheyn et al., 2008b, 2011; Lai et al., 2011). However,
the harvesting of autologous cells arises with a disadvantage, with
additional surgery and time-spending (Aggarwal et al., 2010).
Peptides as Gene Vectors for Bone
Peptides, as the NVGD method, are generally used to enhance
membrane activity and targeting ability. We can notably
cite as an example, a paper where a system using PEG
synthetic hydrogel, functionalized with a collagen-mimetic
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peptide (aka. GFOGER) (Shekaran et al., 2014). In this study,
the hydrogel was applied to murine bone critical-sized defects,
and the authors demonstrated that this functionalized hydrogel
provided increased osteoprogenitor localization in the defect site,
sustained in vivo release of encapsulated molecules, enhanced
bone formation, and induced defect bridging. With respect
to these results, this system demonstrated great potential
for gene delivery despite being developed initially for BMP-
2 delivery. In another study, TGF-β1 was delivered by a
novel NVGD vector called (K)16GRGDSPC chemically linked
to a bone scaffold made with PLGA. Applying this TGF-
β1 functionalized scaffold to rabbit critical size bone defects
significantly increased bone regeneration compared to control
groups (Pan et al., 2014).
Hybrids as Gene Vectors for Bone
To combine many of the beneficial effects of NVGD methods,
hybrid delivery systems can be an attractive approach, in
particular, lipid and polymer integrated materials. PEI
modified with linoleic acid and combined with different
scaffolds such as collagen and gelatine as vehicles was
used to study the expression levels of FGF-2 and BMP-2
after implantation in rat subcutaneous pockets (Rose et al.,
2012). Another example, consisting of an organic/inorganic
hybrid of pDNA-Lipoplex complex co-precipitated within
apatite and loaded onto PLGA sheets, was investigated
to integrate both osteoconductivity and osteoinductivity
(Luong et al., 2009). Results demonstrated that the
organic/inorganic hybrid resulted in improved transfection
efficiency in all groups. To conclude, the co-precipitation
of the DNA-lipoplexes within apatite also resulted in higher
stability and better spatial distribution of DNA delivery
(Luong et al., 2009).
Another option could be to combine natural and synthesized
polymers to optimize NVGD systems. A NVGD consisting of
a positively charged gene vector within gelatine microspheres
and combined with a hydrogel of a crosslinked oligo (PEG-
fumarate) (OPF) was used to investigate the effects of
pBMP-2 in a critical-size rat cranial defect model on bone
formation (Kasper et al., 2005). Surprisingly, there was a lack
of improvement in bone regeneration, possibly due to an
insufficient release of the DNA from the hydrogel (Kasper
et al., 2006). Another team investigated the delivery of pBMP-
2 using a biodegradable branched triacrylate/amine polycationic
polymer (TAPP) that was combined with gelatine microparticles
loaded within a porous tissue-engineered scaffold. In this study,
they investigated the interplay between gelatine degradation,
TAPP degradation, pDNA release, and mineralized matrix
production in a rat calvarial critical-size defect model. The
data showed that the hybrid composite scaffolds did not
generate an enhanced bone regeneration in a critical-size rat
cranial defect, as analyzed by microcomputed tomography
and histology. These results claim, however, those polycationic
polymers with a slow degradation rate can prolong the release
of pDNA from composite scaffolds and suggest that gelatin
microparticles comprising biodegradable polycationic polymers
could be established to release pDNA in an intact polyplex form
(Chew et al., 2011).
New approaches were emerging recently using the engineered
matrices as a vector for targeted DNA construct, most
of the time in the form of a plasmid. Multiple studies
have shown that in vivo implantation of gene activated
scaffolds/hydrogels/matrices/complexes at sites of bone defect
was linked with expression of pDNA and retention for at
least 6 weeks. This was followed by the induction of newly
formed bone in a reproducible, stable, time-dependent, and dose-
dependent manner (Bonadio et al., 1999).
DISCUSSION AND CONCLUSION
NVGD methods stay in the focus of current research because
of promising results in various areas of orthopedic research.
We have shown that the clinical trials registered until now
are mainly based in the area of bone, followed by hip,
shoulder, and tendon for musculoskeletal diseases. However,
the number of publications on non-viral gene delivery is not
directional proportional to the interest in clinical trials in
the different joints and tissues. It seemed that most literature
was found for bone repair, followed by cartilage, IVD, and
ligament approaches.
A common problem of all non-viral methods seemed
to find promising solutions to deliver DNA or RNA with
musculoskeletal specific cells in connective tissues. Significant
conceptual differences exist between gene delivery methods
to isolated cells in vitro and to in vivo or ex vivo to
tissue. The current literature demonstrates the enthusiasm and
powerful approach of non-viral gene systems to the areas
of bone and joint diseases. The limited number of clinical
trials related to non-viral gene delivery may also reflect some
of the challenges that the field of gene therapy has faced
over the past decade due to safety concerns related to viral
vectors. However, as this review demonstrates, many NVGD
methods have significant potential but require further protocol
optimization or longer-term animal studies to determine their
efficacy. Indeed it appears that efficacy and efficiency of
the therapeutic strategy whether it is cell proliferation or
structural restoration of soft or hard tissue, remains one of
the significant challenges of NVGD systems. It is likely that a
“one-shoe fits all” approach will not work for all orthopedic
tissues, and a more targeted approach dependent on cell
type, tissue composition/structure, and disease state/defect size
will be necessary.
Cytotoxicity of viral vectors and the risk of host integration of
these genomes, which might cause unpredicted gene mutations
of the host genome, are clear contra-indicators for viral gene
therapy. Conversely, non-viral gene therapy methods are on the
rise, and here a tremendous variety of delivery methods exist,
as we have listed in this review. In terms of clinical translation
from in vitro to in vivo, a significant hurdle is transducing an
adequate number of cells to enhance the therapeutic parameters
of interest in the target tissue of interest. This can be challenging
for orthopedic tissues that are relatively acellular such as the
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IVD and cartilage but might not be as difficult for repairing
bone that is more cellular and vascularized. However, transfection
efficiency has to be optimized while also taking into account
any effects of cytoxicty, which has been observed for NVGDs
such as cationic polymers and electroporation. On the flip-
side, increased cellularity and vascularization of bone could
lead to off-target and even unwarranted responses in other
tissues but is likely not a problem for disk or cartilage.
Disease state also needs to be considered when transitioning
from in vitro to in vivo and the ability of NVGD systems
to transduce cells within a degenerate tissue environment
that is often catabolic and inflammatory. This may result in
increased turnover, degradation and clearance of the NVGD
system, limiting overall efficacy of the therapeutic strategy
and optimizing NVGD systems to take these parameters
into account, for example, creating polyplexes within MMP-
degradable hydrogels for therapeutic release (Feng et al., 2018)
or EVs that can package multiple genes targeting both tissue
regeneration and inflammation. Also, to direct in vivo translation,
ex vivo culture offers an alternative route whereby cells can
be extracted, manipulated in vitro with NVGD systems, and
then reinserted back into the patient, similar to what is
currently being done for autologous chondrocyte implantation
therapy (Krill et al., 2018). This circumvents problems around
transfection efficiency in vivo. However, it often involves
harvesting cells/tissue from healthy regions and also significant
expansion time ex vivo.
In our view, on the side of carrier-based NVGD, the future
research and potential lie in the areas of EVs in the combination
of miRNA or lncRNA transmission that influence the host
cells with specific functions. Here, we have seen tremendous
potential, with many groups that are interested in how OA
or IVDD could be targeted by transient modification of BMPs
and or inflammatory genes or genes of the ECM, depending
on the application in orthopedics. One of the key attractive
features of NVGD is safety and low immunogenicity. Lipid-based
vectors can be readily endocytosed, tissue-nano-transfection
offers a safe and specific method to transfect single cells with
high efficiency, polymers, both natural and synthetic can be
hybridized to increase the efficiency of delivery and EVs can
be generated from autologous cells packaged with a number
of gene vectors.
On the side of carrier-free and physical methods how to
overcome the cellular membrane, we found that electroporation
(nucleofection) has been applied by many studies with relatively
high efficiencies, both in vitro and in vivo directly on tissue.
EVs are attractive NGVD systems as they demonstrate minimal
immunogenicity, can be readily generated from autologous
human cells in large quantities, can be endocytosed, and loaded
with gene vector of interest. Furthermore, an interesting and
exciting area is the use of tissue nano-transfection, which has
high clinical value with the ability to transfect single cells in vivo
and, in turn generating endogenous EVs with genetic cargo
(Gallego-Perez et al., 2017).
For the IVD, NVGD methods have been primarily investigated
in vitro with some studies using organ culture or in vivo rat or
rabbit models. The type of vectors that have been investigated
range from anti-inflammatory/fibrotic agents, siRNA targeting
anti-apoptotic/catabolic enzymes, or discogenic growth factors
and transcription factors. For the disk, specific considerations
that apply include transducing a relatively acellular tissue.
These particular tissue regions may require different vectors
(NP versus inner or outer AF), ECM (negatively charged
proteoglycans), and disease state. Most in vivo studies have
focused on utilizing synthetic polymers with some success and
therefore highlighting these NVGD methods (Feng et al., 2018).
However, emerging/future areas that could be used by the IVD
could include EVs which could be readily injected or tissue nano-
transfection that could be applied directly to the disk surface.
Furthermore, to truly assessing the safety and efficacy of NVGD
methods for treating painful IVD degeneration and regenerating
the IVD, utilizing relevant animals and assessing parameters that
include pain behaviors seems paramount.
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